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Abstract 
Purpose: To evaluate the clinical impact of the Varian Exact Couch on dose and volume 
coverage to targets and critical structures and tumor control probability (TCP) for 6-MV 
IMRT and Arc Therapy.   
Methods: Five clinical prostate patients were planned with both, 6-MV 8-field IMRT and 6-
MV 2-field RapidArc using the Eclipse treatment planning system (TPS). These plans 
neglected treatment couch attenuation, as is standard clinical practice. Dose distributions 
were then recalculated in Eclipse with the inclusion of the Varian Exact Couch (imaging 
couch top) and the rails in varying configurations.  The changes in dose and coverage were 
evaluated using the DVHs from each plan iteration. We used a tumor control probability 
(TCP) model to calculate losses in tumor control resulting from not accounting for the couch 
top and rails. We also verified dose measurements in a phantom. 
Results: Failure to account for the treatment couch and rails resulted in clinically 
unacceptable dose and volume coverage losses to the target for both IMRT and RapidArc. 
The couch caused average dose losses (relative to plans that ignored the couch) to the 
prostate of 4.2% and 2.0% for IMRT with the rails out and in, respectively, and 3.2% and 
2.9% for RapidArc with the rails out and in, respectively. On average, the percentage of the 
target covered by the prescribed dose dropped to 35% and 84% for IMRT (rails out and in, 
respectively) and to 18% and 17% for RapidArc (rails out and in, respectively). The TCP 
was also reduced by as much as 10.5% (6.3% on average).  Dose and volume coverage 
losses for IMRT plans were primarily due to the rails, while the imaging couch top 
contributed most to losses for RapidArc.  Both the couch top and rails contribute to dose and 
v 
 
coverage losses that can render plans clinically unacceptable.  A follow-up study we 
performed found that the less attenuating unipanel mesh couch top available with the Varian 
Exact couch does not cause a clinically impactful loss of dose or coverage for IMRT but still 
causes an unacceptable loss for RapidArc.  
Conclusions: Both the imaging couch top and rails contribute to dose and coverage loss to a 
degree that, if included, would prevent the plan from meeting clinical planning criteria. 
Therefore, the imaging and mesh couch tops and rails should be accounted for in Arc 
Therapy and the imaging couch and rails only in IMRT treatment planning.  
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Chapter 1  Introduction 
1.1 Statement of Problem 
 The American Cancer Society estimates over 1.5 million new cases of cancer were 
diagnosed in 2010 in the United States (1). Of those, approximately 78% will be treated with 
radiation either alone or in conjunction with other therapies (2).  Among the various types of 
cancer, and of interest to this study, adenocarcinoma of the prostate is the most commonly 
diagnosed cancer in men with an estimated 217,730 newly diagnosed cases and 32,050 
deaths in the United States in 2010.  The radiation therapy treatment options for men 
diagnosed with prostate cancer are brachytherapy or external beam therapy with photons or 
protons (1).  The main objective of any therapeutic-option involving radiation is to 
maximize tumor-control while minimizing toxicity to normal surrounding tissues and 
structures.  With that goal in mind, innovations in the field of diagnostic imaging have 
enabled 3-D imaging of internal anatomy with excellent spatial resolution.  These advances 
provide images that contain information about scattering, absorption, and attenuation of 
photon beams by the anatomical structures, which are essential calculation parameters in any 
treatment planning system. Advances in imaging capabilities have also improved the 
detection of microscopic disease.  The improvement in malignancy-detection has also led to 
an improvement in the ability to treat disease with an increasing ability to spare surrounding 
normal tissues and structures.     
Two of the forms of external beam radiation treatment available to prostate cancer 
patients are intensity modulated radiation therapy (IMRT) and Arc Therapy.  Both treatment 
modalities have the ability to balance the need to provide high, conformal dose to diseased 
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target structures while sparing normal tissues surrounding the tumor. These modalities rely 
on inverse treatment planning, where planning software calculates the optimal fluence to 
achieve the input dose constraints.  IMRT refers to a technique for delivering a nonuniform 
fluence to a target from many gantry angles such that the composite dose is optimized to 
meet input prescription dose.  IMRT dose calculation algorithms achieve an optimal 
distribution of dose within a target by varying the fluence of each incident treatment beam 
by modulating smaller segments of each beam (3).  This modulation can be accomplished 
with the use of multileaf collimators (MLCs), small tungsten alloy collimating rods driven 
by motors to block and shape the delivery fields (4).  The delivery of IMRT can also vary 
depending on how the intensity modulation is performed with the MLC’s: step-and-shoot 
IMRT involves movement of the MLC’s to one-position per segment to achieve intensity 
modulation while dynamic IMRT involves continuous MLC motion for each field (3).  
IMRT treatments are delivered using a fixed number of gantry angles; for example, standard 
clinical prostate cancer IMRT plans have an 8-field beam arrangement (at MD Anderson 
Cancer Center [MDACC]).  In such delivery modalities, the dose is modulated and delivered 
only at specified gantry angles, and is not continuously modulated with gantry angle as is 
the case for Arc Therapy.          
Instead of the gantry being stationary while each treatment field is delivered, it is 
possible to deliver dose continuously while the MLC modulates the beam fluence over 
small, incremental gantry angles.   Intensity modulated therapy delivered with the gantry 
rotating, known as intensity modulated arc therapy (IMAT), was first proposed by Cedric 
Yu in 1995 as an alternative for tomotherapy (5).  IMAT involves dynamic beam-shaping by 
the MLC as the gantry rotates.  To deliver the desired modulated dose, several arcs with 
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different MLC patterns and dose delivery may be necessary.  Initially, this technique was 
implemented using forward planning, while IMRT involves inverse planning, and involved 
calculations of fields at fixed angles that were 5-10 degrees apart, making it more similar to 
IMRT delivery instead the intended continous delivery  (6).   In 2007, Karl Otto developed a 
technique he called volume modulated arc therapy (VMAT)  that allowed for inverse 
planning and dynamic MLC calculation for small gantry angle motions  (7).  This led to the 
advent of several treatment planning and delivery platforms, of most interest to this study, 
Varian RapidArc with the Eclipse treatment planning (Varian Medical Systems, Palo Alto, 
CA).   
With almost 80% of the cancer patient population receiving some form of radiation 
therapy, there is a need for continual research and investigation into methods for ensuring 
adequate and accurate radiation dose to treatment volumes and dose-sparing to critical 
structures.  While treatment prescription and critical structure tolerances vary from 
institution to institution and even physician to physician, there are some treatment 
commonalities such as the use of treatment couches for patient positioning. With few 
exceptions (such as total skin irradiation), patients are positioned prone or supine on a 
treatment couch for radiation therapy.  The patient couch is meant to provide a means for 
reproducible patient positioning. Patients can be further positioned with use of various 
devices such as masks to hold the head and neck in a fixed position or cradles that hold the 
body in fixed position, but these are patient- and treatment-specific devices that are separate 
from the treatment couch.   
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 Given the necessity for the couch to be rigid enough to support large patients without 
sagging, the construction material of the treatment couch has two important constraints:  it 
must be strong and durable enough to meet manufacturer’s sag tolerances and it should be 
radio-transparent enough to not appreciably attenuate the therapy beam when radiation fields 
intersect the couch.  The couch tops are generally made of carbon fiber, which has a low-
density, and are, therefore, considered to be radio translucent.  Additionally, the Varian 
Exact couch used in this study is supported by carbon fiber rails that allow the couch to 
move forward and backward for correct patient positioning and can also be moved laterally 
in and out.  Due to the assumption of radio translucence, the effects of the couch and rails on 
the treatment beam are not generally included in treatment planning or other dose 
calculations even when the beam traverses the couch and rails during treatment.   However, 
studies investigating beam attenuation by treatment couches and rails have shown relatively 
large amounts of beam attenuation at angles over which the beam transverses the couch and 
rails.   
In a study by McCormack et al in 2005, the magnitude of the attenuation by a Sinmed 
Posisert treatment couch top over posterior oblique gantry angles was measured in a solid 
water phantom by an isocentrically placed ion chamber. They found that for a 6-MV photon 
beam of field size 10 cm x 5 cm, there was substantial attenuation by the couch top; 2% at 
normal incidence between the couch and beam and reaching a maximum of 9% (8). A study 
by Gerig et al in 2010, evaluated the attenuation properties of two different treatment 
couches: the CIVCO and Medical Intelligence couches, using the same method as the 
previously mentioned study.  They found that each couch had different beam attenuation 
properties and that the maximum beam attenuation was 7% (9). A study by Njeh et al in 
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2009, repeated these measurements for a different couch top, the BrainLAB imaging couch, 
and found a maximum attenuation of 8.3% at a 120 degree gangtry angle for a 6 MV 
treatment beam (10).  A study published by Mihaylov et al in 2010 within a few months of 
the study by Njeh et al found a maximum attenuation of 8% by the BrainLab couch top for a 
6 MV treatment beam (11).  This helps to demonstrate that although the magnitude of 
attenuation varies depending on the manufacturer and specific compostion of the couch top, 
that there has been reproducibility of results in the literature when the same couches are 
evaluated.      
All of the aforementioned studies evaluated the relative attenuation on various treatment 
couch tops, however, they did not evaluate the impact that the support rails have if traversed 
by the beam.  Because the support rails act to support the couch top and prevent sag when 
substantial weight is placed upon it, it may be expected that the rails would attenuate more 
than the couch top.  Studies evaluating the degree of attenuation when both the treatment 
couch top and rails are traversed found up to 17% attenuation for some posterior oblique 
fields (12,13,14).   The attenuation from the rail structures is much higher than from the 
couch top alone compared to any study mentioned. However, as Mihaylov et al in 2008 
noted, these couch rails can be moved to avoid the beam path for posterior oblique fields, 
making its contribution to attenuation interesting but potentially not clinically revelant (11).  
Nevertheless, clinical practice shows that the couch rails are often not moved during 
treatment. In such cases, attenuation from the rails does have the potential to impact clinical 
care. Moreover, while moving the rail to avoid the beams is feasible for IMRT treatments, it 
is not feasible for Arc Therapy treatments that involve intersections with the couch and rails 
since the delivery is continious.  So while the attenuation that needs to be accounted for may 
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be reduced to between 2% and 9% when the rails are moved out of the treatment beam for 
IMRT, the attenuation of up to 17% by the couch top and rails is often not avoided in 
clinical IMRT practice and cannot be avoided for Arc Therapy.     
 The problem inferred by the large attenuations observed in these studies is the 
potential effect on patients treated with posterior fields.  Since the treatment couch is not 
normally accounted for in treatment planning, the dosimetric effect of the attenuation on 
target and normal tissue structures cannot be anticipated.  The attenuation through posterior 
fields could cause a loss of dose and coverage of structures along the path.  The result would 
be, at the very least, the actual dose distribution not matching the plan with no clinical 
consequence to treatment or, at most, an inadequate dose delivered to the target for tumor-
control as assumed by the prescription dose. Despite the large attenuation demonstrated by 
the couch top and rails in the literature, only one study to-date has evaluated what target 
dose perturbation can result from the attenuation on patient cases (14).  For the most part, 
the limiting aspect in evaluating the target dose pertubation is incorporation of the couch top 
and rails in a treatment planning system (TPS) to quantify the dose effect.  TPS calculate 
dose using information from 3-dimensional CT data sets of patient anatomy.  When a patient 
has a planning or simulation CT, they are positioned as they would be for actual treatment; 
however, the couch top they are positioned on is not necessarily the same as the treatment 
couch.  The simulation couch can be of different dimensions or composition as the treatment 
couch.  Consequently, information about the treatment couch is not available from the 
patient’s simulation scan and cannot be included in treatment planning. Furthermore, even if 
the treatment couch and imaging couch are the same, the CT data of the imaging couch is 
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removed from the plan before treatment planning so no couch-related effects are taken into 
account.   
 There are techniques available to incorporate the treatment couch into the patient CT 
image dataset, and thereby include this information in the treatment planning process. In 
order to incorporate the treatment couch and/or rails in a treatment planning system, the 
three studies to be discussed used a similar methodology.  The first, a study published by 
Myint et al in 2006, incorporated the couch top into a TPS by taking a CT image of the 
Medtec therapy couch top, transferring the CT DICOM RT images to the TPS where dose 
calculations were performed as normal for other structures (13).  The next study published 
by Mihaylov et al in 2008 imported the couch CT data set into a TPS by taking CT 
simulation images of each of the couch top components, modifying the couch dimensions 
and CT properties to match the manufacturer’s specifications in the TPS, and contouring the 
couch components so the TPS could calculate dose through the couch top (11).  The basic 
methodology for incorporation of the couch top was the same for these first two studies; 
however, the rails associated with the couch tops were not incorporated.  Only one study 
found in the literature attempted to include the rails in order to look at their dosimetric 
impact.  This study published by Prooijen et al in 2010, like the others, incorporated the 
couch tops by importing CT images of those components.  However, for the non-mobile 
couch parts, including the rails one of the couches evaluated, the authors created ROI’s 
within the TPS and assigned uniform density values consistent with the overall density of 
the rails, failing to account for the heterogeneity of the rails (14).                      
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 In the study by Myint et al, evaluating dosimetric impact of the couch using the 
methodology mentioned previously, it was found that inclusion of the couch top into their 
TPS reduced the dose error from 7.4% to less than 1.4% as determined via dose 
measurements in a phantom with and without the couch top being taken into account (13).  
Similarly, the study by Mihaylov et al found agreement with their TPS to within 1.7% when 
the couch top was included. They further concluded that the couch top increases the skin 
dose to a patient for posterior fields as determined by measuring PDD’s of beams passing 
through the couch top (11).   The most extensive study of dosimetric impact of the treatment 
couch and rails was done by Prooijen et al in 2010.  They found that their TPS agreed to 
within 3% for calculated dose versus measured dose in a phantom when the couch top was 
included in the TPS and within 2% for a single patient case (14).  They went further by 
evaluating the loss of dose and coverage to the PTV and CTV of five previous IMRT 
clinical cases that involved posterior fields when the couch top and rails were included in the 
dose calculations. This was done by preserving the beam angles and MU’s for the clinical 
plan that was optimized without the presence of the couch and rails.  They found a loss of 
3% coverage to the PTV (as defined by the 95% isodose line), 1% for CTV coverage, and a 
point dose reduction of 8+ 3% (14).  However, the disease sites, prescriptions, and beam 
arrangements used in these five cases were not divulged and cannot be compared to our 
study.        
Despite the demonstration of dosimetric impact of the couch top and/or rails by these 
studies, a simplified way to include the couch top and rails in clinical patient plans has not, 
to the author’s knowledge, been explored in the literature.  Also, evaluation of the impact on 
critical normal tissue structures has not been evaluated which is potentially important as 
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treatment planning often involves using normal tissue constraints to create appropriate 
treatment plans.  The long term impact of ignoring the couch and rails in treatment planning 
on tumor control probability (TCP) has also not been explored. Finally, no previous studies 
have evaluated the impact of the treatment couch on Arc Therapy, although the paper by 
Prooijen et al mentions this as an important future direction of research (14).   This thesis 
extends upon the work done by the various background studies, in that the clinical impact to 
both target and critical structures is evaluated for both IMRT and Arc Therapy for both the 
couch top and rails individually using Varian Eclipse treatment planning system (Varian 
Medical Systems, Palo Alto, CA). This work uses Eclipse’s couch top and rail model after 
first verifying its accuracy with measurements.  
1.2 Hypothesis and Specific Aims 
We hypothesized that the presence of the Varian Exact imaging couch top and rails 
would not demonstrate a clinical impact for IMRT and Arc Therapy. A clinical impact was 
defined to be a change that would cause a failure of the plan based on clinical planning 
criteria used in our clinic: 98% coverage of prescription dose to the prostate, 95% to the 
PTV, meeting of normal tissue DVH constraints, or a reduction in tumor control probability 
(TCP).  This was assessed by completion of the following three aims:  
1. Measure the relative attenuation as a function of gantry angle for a 6-MV photon 
beam to establish the dose attenuating properties of the Varian Exact imaging couch 
top, mesh couch top, and rails. 
2. Validate the Eclipse TPS couch model by evaluating absolute dose agreement 
between the Eclipse TPS dose calculations and dose measured in IMRT QA phantom 
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for five prostate cancer patients planned with both 8-field IMRT and 2-arc RapidArc 
plans.   
3. Compare the DVH’s for each clinical (no couch) plan and subsequent plans that 
include the treatment couch and rails to evaluate the dose and coverage loss to 
targets and critical normal tissue structures and tumor control probability (TCP) 
reduction. 
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Chapter 2 Materials and Methods 
2.1 Relative Attenuation Measurements 
 The relative attenuation of two Varian Exact couch inserts (imaging and mesh) and 
the rails were measured for a 6-MV photon beam on a Varian Clinac® 2100C linear 
accelerator (Varian Medical Systems, Palo Alto, CA).  A PTW Farmer ion chamber (PTW, 
Freiburg, Germany) was positioned isocentrically at a height of 10 cm above the couch 
using the linear accelerator’s (linac’s) alignment lasers.  Once aligned, a PMMA build-up 
cap of 7.6 mm wall thickness (total thickness of 1.52 cm) thickness to maintain electronic 
equilibrium for a 6-MV beam was placed over the ion chamber.   A CNMC Model 206 
electrometer (CNMC, Nashville, TN) was used to take the charge readings from the ion 
chamber. 
 A 10x10 cm2 field size and machine output of 50 MU was used for all 
measurements.  An initial reading at 0, 90, and 270 degrees of gantry rotation was taken to 
ensure proper alignment of the chamber’s active volume to linac isocenter. Specifically, the 
chamber position was adjusted until these three angles produced readings that agreed within 
0.1 nC.  Two readings were then taken at each angle over a range of angles. These 
measurements were made at small angle increments to ensure adequate sampling of 
attenuation of the couch and rails.  First, the imaging couch top was used and measurements 
were taken with the rails in their outmost position.  The measurements were then repeated 
for the imaging couch top with the rails moved in their innermost position.  Finally, the 
couch top was replaced with the mesh couch top and the measurements repeated with the 
rails out.   
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 Relative beam attenuation as a function of gantry angle was assessed using the 
average of the two reading.  The average of the reading taken at 0 degree gantry rotation was 
assumed to be 0% attenuation as the beam does not pass through an attenuating structure 
before encountering the ion chamber.  The relative attenuation for all other gantry angles 
was then calculated as a percent difference between the measured reading and the reading at 
0 degrees gantry rotation. 
 
Equation 2-1 Percent difference equation 
 
 Where M is ion chamber reading in nano Coulombs at a gantry angle x.  
2.2 Varian Eclipse Treatment Planning System 
2.2.1 IMRT Planning 
Five prostate cancer patients with clinically contoured CT simulation images in the 
Eclipse TPS database were chosen for inclusion in the study.  All patients had intact 
prostates and were planned with a prescription dose of 76 Gy: 2 Gy per fraction for 38 
fractions. This is the standard fractionation at MDACC.  All patients were planned with the 
MDACC standard 8-beam field arrangement at gantry angles of 225, 260, 295, 330, 30, 65, 
100, and 135 degrees with 6-MV photon beams as seen in Figure 2-1.  
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Figure 2-1.  MDACC clinical 8-field IMRT beam arrangement.  
 
The collimator and couch rotation were set to 0 degrees for all plans.  Clinically, the 
prostate and PTV structures are contoured by the physician and have clinical dose and 
coverage constraints assigned to them. A plan was considered to be clinically acceptable 
when at least 98% of the prostate and 95% of the planning tumor volume (PTV) was 
covered by the prescription dose and the following DVH dose constraints were met for the 
critical normal tissue structures.  The clinical DVH constraints used for prostate patients is 
shown below in Table 2-1. 
Structure 
Clinical DVH 
Constraints 
Rectum 40 Gy<60% 
  45 Gy<50% 
  60 Gy<40% 
  70 Gy<20% 
  75.6 Gy<15% 
  78-80 Gy <5% 
Bladder 70 Gy<20% 
Table 2-1.   MDACC clinical DVH planning constraints for external photon beam treatment of the prostate. 
 
 These five plans were optimized in Eclipse version 8.6 (Varian Medical Systems, 
Palo Alto, CA) without the couch or rails included in the plans. This will be referred to as 
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the IMRT clinical scenario plans because ignoring the couch is the standard clinical 
situation.  The Eclipse TPS IMRT optimization algorithm uses inverse-planning based on 
DVH constraint inputs to calculate the MU’s and dynamic MLC pattern for each IMRT 
field.  The MLC leaf motion pattern was calculated using version 8.6.15 of the leaf motion 
calculation algorithm in Eclipse.  The final dose was calculated using the Anisotropic 
Analytical Algorithm (AAA), which is a 3D pencil beam convolution algorithm that uses 
Monte Carlo derived models for primary and scattered photons.  Plan normalization, when 
necessary, was performed by normalizing the plan for PTV coverage.  All plans were 
generated using machine parameters for the same Varian Clinac linear accelerator.   
To evaluate the effects of the couch top and rails, the clinical scenario plans were 
copied and the couch top and rail structures were inserted into the plan in the following 
configurations for a total of three additional plans for each patient: 
1. Imaging insert and rails in the out position (referred to as the “rails out” plan), 
representing a scenario in which the rails are not moved during treatment 
2. Imaging insert and rails in the in position (referred to as the “rails in” plan), also 
representing a scenario in which the rails are not moved during treatment 
3. Imaging insert only (referred to as the “couch top only” plan), representing a 
scenario where the rails are moved to avoid the beam during IMRT delivery  
A sample image of the IMRT beam arrangement for one patient’s IMRT rails out and rails 
in plans are shown below in Figure 2-2. 
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Figure 2-2.   8-Field Beam Arrangement for IMRT with Imaging Couch Top and Rails. Rails Out (left panel), 
Rails In (right panel). 
 
After insertion of the couch top and/or rail structures, the AAA algorithm was used 
to recalculate the final dose to the structures.  These plans with the couch and/or rail 
structures were then renormalized so that the MU’s of the plan matched the MU’s of the 
clinical scenario plan. For 4 of the IMRT plans it was possible to renormalize such that there 
was a 0% difference between the MUs between plans, to machine precision. For 1 patient 
there was residual mismatch of 4 MUs for a total difference of 0.35% between the total 
MU’s of the clinical scenario and the subsequent plans that included the couch and rails.  
This renormalization was essential to ensure that any differences between the clinical 
scenario plan and the couch plans would be solely attributable to the effect of the patient 
support structures.    
2.2.2 Varian RapidArc Planning 
 The VMAT delivery used in this study was Varian’s RapidArc (Varian Medical 
Systems, Palo Alto, CA), which was planned in Eclipse version 8.6.  The same five patients 
that were planned with IMRT were also planned with RapidArc.  All patients were planned 
using the same parameters and constraints as the IMRT plans listed in the previous section.  
Two arcs were used for all the plans; one arc field beginning at a gantry rotation of 180.1 
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degrees and rotating to 179.9 degree clockwise with a 30 degree collimator rotation, and the 
other beginning at 179.9 degrees and rotating to 180.1 degrees counter clockwise with a 330 
degree collimator rotation.  The couch rotation was set to 0 degrees for both fields and 
neither the couch top nor the rails were included in the optimized plan per clinical practice.   
The X and Y jaws were adjusted as needed on the beam’s eye view to encompass the target 
before optimization.  Varian’s RapidArc Progressive Resolution Optimizer (PRO) algorithm 
was used to optimize the plans, as developed from the work by Karl Otto using inverse-
planning based on dose-volume input constraints.  The result is a dynamic MLC pattern, 
variable gantry rotation, and variable dose rate.  The final dose distribution is calculated 
using the AAA algorithm.  A sample clinical scenario RapidArc beam arrangement is shown 
below in Figure 2-3. 
 
Figure 2-3.   Sample 2-field RapidArc beam arrangement 
 
 To evaluate the effects of the couch top and rails, these RapidArc clinical scenario 
plans were copied and the couch top and rail structures were inserted into the plan in the 
following configurations for a total of three additional plans for each patient’s clinical 
scenario plan: 
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1. Imaging insert and rails in the out position (referred to as the “rails out” plan), 
representing a scenario in which the rails are not moved during treatment 
2. Imaging insert and rails in the in position (referred to as the “rails in” plan), also 
representing a scenario in which the rails are not moved 
3. Imaging insert only (referred to as the “couch top only” plan).  This scenario is 
not clinically achievable in arc therapy but was evaluated for RapidArc to assess 
the effect of the couch top and rails individually.  
A sample image of the RapidArc beam arrangement for one patient’s rails out and rails in 
plans are shown below in Figure 2-4. 
  
Figure 2-4.  2-arc beam arrangement for RapidArc with the couch top and rails. Left panel shows rails out plan 
and right panel shows rails in plan. 
 
After insertion of the couch top and/or rail structures, the AAA algorithm was used 
to calculate the final dose to the structures.  These plans with the couch and/or rail structures 
were then renormalized so that the MU’s of these plans matched exactly the MU’s of the 
clinical scenario plan for each patient.  This was to ensure that any differences between the 
clinical scenario and these plans would be solely attributable to the effect of the patient 
support structures.   
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2.2.3 Varian Exact Couch 
 The Varian Exact couch (Varian Medical Systems, Palo Alto, CA) is positioned with 
respect to the Varian linear accelerator it is associated with such that the couch lateral, 
longitudinal, and rotational coordinates are displayed on the linac and within the linac’s 
treatment console display.  The couch is composed of the following components: hand 
pendants to control the motion of the linac and its components, a lift base to raise and lower 
the couch, removable end panels that can be used to attach patient immobilization devices, 
movable structural rails to support the couch top panel, and removable flat panel (imaging 
couch top) and unipanel (mesh couch top) treatment insert structures (15).  The imaging 
couch top and support rails are shown below in Figure 2-5 and Figure 2-6.   
 
Figure 2-5.  Varian Exact imaging couch top and support rails 
 
Figure 2-6.  Movable support rails on Varian Exact Couch 
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 The Exact Couch structures (various couch tops and movable support rails) are 
available as insertable structures in the Eclipse TPS.  The dimensions (i.e. thickness and CT 
number) of these structural components are the same as the manufacturer’s specifications 
and the densities of the structures are included in HU numbers assigned to each couch 
component.  The default settings for the couch components in the Eclipse TPS were used in 
this study.  
2.3 Point Dose Evaluation 
2.3.1 Plan Verification: IMRT QA 
The clinical IMRT QA protocol at MDACC was used to evaluate the point dose 
agreement between the measured point dose in the IMRT QA hybrid phantom for the 
clinical scenario IMRT and RapidArc plans and the expected dose calculated in the TPS in 
the hybrid QA phantom.  The clinical passing criterion at MDACC requires the dose 
measurement and calculated by the TPS in the hybrid phantom to match within + 3%.  A CT 
image set of the IMRT QA phantom (IBA Dosimetry Bartlett, TN) with CC04 ion chamber, 
inner radius of 2 mm, and a sensitivity of 94 x 107 Gy/C (IBA Dosimetry Bartlett, TN) was 
imported into the Eclipse TPS and set as the default image for IMRT QA verification plans.  
The active volume of the ion chamber was contoured so that doses to the ion chamber could 
be calculated for a given plan.       
To calculate the point dose in the Eclipse TPS, a verification plan was made for each 
clinical scenario plan and additional plan that included the couch top and/or rails.  The 
verification plan was created by copying the IMRT or RapidArc plan onto the image of the 
hybrid phantom and re-calculating the dose-volume with the same fluence and MU’s as the 
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original plan, which was achieved by using the same percent normalization for the hybrid 
plans as was used for the clinical plans.  A sample RapidArc clinical scenario hybrid plan is 
shown below in Figure 2-7.   
 
Figure 2-7.  Sample hybrid plan for clinical scenario RapidArc plan 
 
To calculate the dose to the plans that were modified by including the couch top and 
rails, the couch top and rails were imported into the verification plan and then the plans were 
recalculated with the AAA algorithm.  Again, to maintain the same MU’s as the clinical 
scenario plan with the couch and rails included, the hybrid plans were normalized to the 
same value as the patient plans that included the couch and rail. The calculated dose to the 
hybrid phantom’s ion chamber was recorded for each plan for comparison to measured 
values.  A sample RapidArc rails out hybrid plan is shown below in Figure 2-8. 
 
Figure 2-8.  Sample hybrid plan for RapidArc with imaging couch top and rails 
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Point dose measurements for comparison to the calculated doses were made by 
following the IMRT QA procedure at MDACC.  First, a dose factor for the machine output 
was needed to convert ion chamber measurements to dose.  To get this factor, the IMRT QA 
phantom was positioned on the Varian Exact treatment couch and aligned with the 
machine’s lasers such that the active volume of the ion chamber was at isocenter.  The field 
size was set to 10 x 10 cm2, the machine set to 200 MU using a 6 MV photon beam.  Three 
readings were recorded with the gantry at each of 90 and 270 degrees, and the results were 
averaged.  That average ion chamber reading was then used to calculate the dose factor 
using Equation 2-2 assuming a transfer factor of 113.2 cGy for a 6-MV photon beam.  
 
 
Equation 2-2.   MDACC clinical IMRT QA dose factor equation 
 
Because the clinical scenario plans had the same MUs as their respective iterations 
that included the couch and rails, the fields for the clinical-scenario plan was exported from 
Eclipse and scheduled in Mosaiq for delivery on a Varian Clinac iX linac.  Each patient plan 
(5 IMRT and 5 Rapid Arc plans) was delivered twice; once with the rails in and once with 
the rails in the out position.  No measurement was taken without the couch top or rails as 
this is not clinically feasible.  The ion chamber reading for each field was recorded, 
converted to dose using the dose factor, and summed (8 fields for IMRT and 2 fields for 
RapidArc) to compare to the absolute point dose calculation from the Eclipse TPS.   
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Comparisons between calculated and measured values for the IMRT and RapidArc 
point dose measurements were made by evaluating the percent difference between the 
calculated and measured value of interest using Equation 2-3. 
 
Equation 2-3.  Percent difference equation 
 
2.4 DVH Analysis 
2.4.1 Dose  
 Evaluation of the dosimetric impact of the couch top and rails was performed using 
the tabular DVH information generated by each plan in the Eclipse TPS.  The tabular DVH 
information containing the absolute volume versus absolute dose for each structure of 
interest was exported and evaluated using Excel.  Information about the minimum, 
maximum, and mean dose to each structure was exported along with the DVH information.  
The impact of the couch top and rails on dose to the prostate and PTV were evaluated by 
subtracting the minimum, maximum, and mean dose for each structure in the plans with the 
couch top or rails from the respective structure in the clinical scenario plan for both IMRT 
and RapidArc.  This subtraction did not represent difference between the same two spatial 
locations within a structure for different plans, but rather, the difference between the 
maximums, minimums, and means without respect to spatial location within a structure.   
 Spatial information about dose differences was obtained graphically with plan 
subtractions. The dose distribution for each plan with patient support structures was 
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subtracted from the dose distribution of the clinical scenario plan and displayed visually on 
the patient CT image, providing a visual image of the spatial distributions of dose 
differences. However, this spatial information was not exportable using Eclipse.   
2.4.2 Relative volume coverage 
 The relative volume coverage for the prostate, PTV, bladder, and rectum were 
evaluated by calculating the relative volume of the structure covered by each dose bin.  The 
total absolute volume of a given structure was set to the volume of the structure covered at 
the 0 Gy dose bin.  The relative volume was then calculated by taking the ratio of the 
absolute volume of the structure at each dose bin divided by the absolute volume covered at 
the 0 Gy dose bin as shown in Equation 2-4. 
 
Equation 2-4.  Equation for relative volume 
Where x is the volume of the structure covered by a dose of at least x. 
2.5 Tumor Control Probability (TCP) 
2.5.1 Niemierko and Goitein TCP Model 
The TCP for each plan was calculated using an available script (16). This script is 
based on a clinically implementable TCP model previously developed by Niemierko and 
Goitein (17) for an inhomogeneously irradiated tumor derived from principles of 
mechanistic cell kill and Poisson statistics. The script uses Equation 2-5 to calculate the TCP 
using a differential DVH:  
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Equation 2-5.  Niemierko and Goitein TCP equation 
 
TCD50 is the dose to the tumor needed to control 50% of the tumor cells when it is 
homogeneously irradiated, and γ50 is a unitless parameter that describes the slope of the 
dose-response curve at the value for TCD50.  Both the TCD50 and γ50 parameters are obtained 
from fitting clinical outcome data to dose-response curves.  The last parameter into the TCP 
equation is the equivalent uniform dose (EUD) which is the biologically equivalent dose 
that, if given uniformly, will lead to the same cell kill in the tumor volume as the actual non-
uniform dose distribution.  The EUD is calculated using input DVH information as shown in 
Equation 2-6.  
    
 
Equation 2-6.  Equivalent uniform dose (EUD) equation used in Niemierko and Goitein TCP model 
 
Where Vi and Di are quantities from the input DVH information; specifically, Vi is unitless 
and represents the ith partial volume receiving a dose of Di. The parameter ‘a’ is a unitless 
parameter that is specific to the tumor of interest and describes the dose-volume effect.  
Additional inputs into script are required that are not seen in the equations above.  
Values for α/β, which describes the steepness of the dose-response curve, and the dose 
fractionation of the plans are required inputs since they were used to fit the clinical-response 
data from which TCD50 and γ50 were obtained.  User inputs into the script included the DVH 
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information from which the EUD was calculated, a value for ‘a’, TCD50, γ50, α/β, and the 
dose fractionation of the patient outcome cases used to derive the input parameters.   
Values for dose-response-dependant parameters mentioned above were taken from 
studies by Levegrun et al and Wu et al.   Levegrun et al fit the dose-response data of 103 
prostate cancer patients with 2 Gy treatment fractions to obtain values for TCD50 and γ50 for 
low, intermediate, and high risk prostate cancer patients using the assumptions of the 
Niemierko model (18).  The value for ‘a’of -10 was taken from a study evaluating prostate 
cancer cases with this model by Wu et al (19).  The value of α/β of 10 Gy was used as it is a 
common value associated with prostate tumors, however, as noted in the literature, reported 
values can be as low as 1.5 Gy (18).  Assuming an intermediate-risk patient population, we 
used a TCD50 of 67.75 Gy, with a corresponding γ50 of 3.6, an α/β of 10 Gy, and fractions of 
2-Gy.   
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Chapter 3  Results 
3.1 Relative Attenuation Versus Gantry Angle 
The measured attenuation of the beam by the couch as a function of gantry angle is 
shown in Figure 3-1 below, and in tabular form in Table 3-1.  Relative attenuation was 
normalized to 0 degrees, corresponding to an anterior beam. 
 
Figure 3-1. Relative attenuation of Varian Exact couch tops and rails 
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Gantry 
Angle 
Relative Attenuation 
(%) Mesh Top, Rails 
Out 
Relative Attenuation 
(%) Imaging Top, 
Rails Out 
Relative Attenuation 
(%) Imaging Top, Rails 
In 
0 0.0% 0.0% 0.0% 
90 0.6% 0.1% 0.1% 
100 0.6% 0.2% 0.3% 
105 0.8% 0.2% 0.4% 
110 1.1% 0.7% 0.8% 
115 -12.0% -5.0% -4.7% 
120 -17.1% -21.8% -4.4% 
125 -3.5% -7.7% -3.7% 
130 -4.3% -7.7% -2.9% 
135 -9.6% -12.6% -2.3% 
140 0.7% -2.2% -1.9% 
145 0.4% -1.9% -1.1% 
150 N/A -1.7% -0.9% 
155 N/A N/A N/A 
160 N/A -1.3% -11.5% 
165 N/A N/A -12.3% 
170 N/A -1.4% -12.3% 
175 N/A N/A -5.5% 
180 1.0% -1.3% 0.0% 
185 N/A N/A -3.3% 
190 N/A -1.2% -12.6% 
195 N/A N/A -14.3% 
200 N/A -1.3% -11.6% 
205 N/A N/A -10.5% 
210 N/A N/A -1.0% 
215 0.2% -1.9% -1.3% 
220 0.5% -2.1% -1.8% 
225 -10.0% -13.2% -2.5% 
230 -5.1% -7.9% -2.9% 
235 -4.4% -8.3% -3.7% 
240 -17.5% -20.5% -4.6% 
245 -12.1% -4.8% -5.2% 
250 0.7% 0.4% 0.6% 
255 0.2% -0.1% 0.2% 
260 0.2% 0.1% 0.3% 
270 0.1% 0.0% 0.0% 
Table 3-1. Relative attenuation of Varian Exact imaging and mesh top with rails.  The pink highlighting 
represents angles over which the couch top and rails intersected with the beam.  
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The relative attenuation was as large as 21.8% when both the Exact imaging insert 
and rails were traversed in the rails out position. The relative attenuation of the mesh insert 
was as large as 17.1% when the Exact mesh insert and rails were both traversed in the rails 
out position.  The relative attenuation was as large as 14.3% when the Exact mesh insert and 
rails were traversed in the rails in position.  
3.2 IMRT and RapidArc Plans 
3.2.1 IMRT DVH’s 
 The DVH’s for each patient’s IMRT plans (clinical scenario, rails out, rails in, 
imaging couch only) are displayed below in Figure 3-2 through Figure 3-6.  They are 
displayed as relative structure volume versus absolute dose with the scale begins at 50 Gy 
(5000 cGy) for all the plans to better visualize the areas of difference between the plans.  A 
full view of the entire DVH’s for these plans can be seen in the appendix.  The PTV, 
prostate, rectum, and bladder are displayed in blue, red, green, and yellow in each figure, 
respectively.  Each clinical scenario plan, which is the outer most pair of prostate and PTV 
lines in each plan, passed MDACC’s planning criteria of at least 98% coverage of the 
prostate and 95% coverage of the PTV by the prescription dose of 76 Gy.  The next pair of 
PTV and prostate DVH lines (those shifted to the left but closest to the clinical scenario) are 
for both the plans with the rails in and the imaging couch top only for all patients. This 
indicates that the loss of coverage to the structures is a result of the effects of the imaging 
couch top alone and that the rails are not intersected in this position for this treatment beam 
arrangement as shown in Figure 2-2 in section 2.2.1.  The left-most set of prostate and PTV 
DVH lines, the greatest dose reduction from the clinical scenario, are for the plan with the 
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rails out in all the patients.  This indicates that the most coverage to the target structures is 
lost when both the imaging couch top and rails are intersected (as is shown in Figure 2-2).  
 The effect to the critical structures is harder to visualize with this scale on the DVH’s 
and will be addressed separately in 3.4.3 Critical Structures: IMRT.     
 
Figure 3-2.  DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient 
1 showing structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and 
bladder are displayed in blue, red, green, and yellow, respectively 
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Figure 3-3.  DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient 
2 showing structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and 
bladder are displayed in blue, red, green, and yellow, respectively 
 
Figure 3-4.  DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient 
3 showing structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and 
bladder are displayed in blue, red, green, and yellow, respectively 
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Figure 3-5.  DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient 
4 showing structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and 
bladder are displayed in blue, red, green, and yellow, respectively 
 
Figure 3-6 DVH for all IMRT plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for patient 5 
showing structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and bladder 
are displayed in blue, red, green, and yellow, respectively 
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3.2.2 IMRT MU’s 
 The MU’s used for each patient's IMRT clinical scenario plan and all subsequent 
iterations of the plan including the couch top and rails is displayed below in Figure 3-7 as a 
function of beam angle. For the one patient whose MUs were only able to be renormalized 
within 0.35% when the couch and rails were included (patient 3, as mentioned in section 
2.2.1), the renormalized MUs, as compared to the clinical scenario plan, resulted in the 
fields at 295, 260, 135, and 100 degrees that were higher by 1 MU each as compared to the 
clinical scenario MU’s.  The trends analysis of this patient’s plans was consistent with the 
other plans and this error was, therefore, not considered to impact the results. 
 
Figure 3-7.  TPS optimized MU’s for each gantry angle ssed for IMRT plans 
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 Most of the MUs were typically delivered at 330 and 30 degrees (e.g Patients 3,4, 
and 5), corresponding to anterior directions. There were typically a minimal of MUs 
delivered through lateral directions at 295 and 65 degrees (eg Patients 2, 3, and 4). However, 
this was not universally true as patient 1 had a nearly inverted trend and patient 5 had more 
MU’s through the lateral angles than the posterior angles at 225 and 135 degrees. 
The number of MU’s per field varied for each patient.  This is to be expected as the 
patient size and specific anatomical properties varied and the TPS optimization is patient-
specific to these variables in addition to the constraint parameters.  The numerical MU 
values for each patient’s plans are displayed below in Table 3-2 through Table 3-6, below. 
Patient 1     
Beam Angle 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
225 98 98 98 98 
260 102 102 102 102 
295 96 96 96 96 
330 83 83 83 83 
30 85 85 85 85 
65 98 98 98 98 
100 103 103 103 103 
135 98 98 98 98 
Plan 
Normalization: 
100% to 98% 
of PTV 94.1% 94.1% 94.1% 
Table 3-2.  MU and normalization values for each plan iteration for patient 1 
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Patient 2     
Beam Angle 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
225 148 148 148 148 
260 127 127 127 127 
295 95 95 95 95 
330 129 129 129 129 
30 130 130 130 130 
65 100 100 100 100 
100 126 126 126 126 
135 132 132 132 132 
Plan 
Normalization: 
100% to 96% 
of PTV 94.6% 94.6% 94.6% 
Table 3-3.  MU and normalization values for each plan iteration for patient 2 
 
 
Patient 3  
 
   
Beam Angle 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
225 94 94 94 94 
260 101 102 102 102 
295 88 89 89 89 
330 134 134 134 134 
30 122 122 122 122 
65 88 88 88 88 
100 112 113 113 113 
135 98 99 99 99 
Plan 
Normalization: 
100% to 96% 
of PTV 94.6% 94.6% 94.6% 
Table 3-4.  MU and normalization values for each plan iteration for patient 3.  The numbers in bold are the 
angles that differed in MU compared to the clinical scenario plan. 
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Patient 4     
Beam Angle 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
225 137 137 137 137 
260 92 92 92 92 
295 72 72 72 72 
330 152 152 152 152 
30 137 137 137 137 
65 77 77 77 77 
100 96 96 96 96 
135 113 113 113 113 
Plan 
Normalization: 
100% to 96% 
of PTV 93.5% 93.5% 93.5% 
Table 3-5.  MU and normalization values for each plan iteration for patient 4 
Patient 5     
Beam Angle 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
225 102 102 102 102 
260 130 130 130 130 
295 110 110 110 110 
330 172 172 172 172 
30 156 156 156 156 
65 103 103 103 103 
100 127 127 127 127 
135 104 104 104 104 
Plan 
Normalization: 
100% to 97% 
of PTV 94.2% 94.2% 94.2% 
Table 3-6.  MU and normalization values for each plan iteration for patient 5 
 
3.2.3 IMRT Sample Plans 
 A sample patient clinical scenario IMRT plan next to its subsequent iterations (rails 
out, rails in, and couch top only) for the same CT slice are displayed below in Figures 3-8 
through 3-10 with the same isodose lines.  The clinical scenario plan slice on the left panel 
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of each figure shows complete coverage of the prostate (in blue colorwash) by the 76 Gy 
isodose line (in red), indicating complete coverage of the structure on that CT slice when the 
couch and rails are not included in the plan, as is clinical practice at MDACC.  The image in 
the right panel show the changes in the prescription isodose coverage of the target when the 
couch and rails are considered.   Other representative plans are shown in the appendix.   
Figure 3-8 below shows the isodose coverage of the prostate with the rails out as 
compared to the coverage for the clinical scenario on the same CT slice; the prescription 
isodose line is no longer covering the prostate as it was in the clinical scenario plan.  This 
‘breaking’ of the prescription isodose line would not be clinically acceptable for plan 
approval.   
 
Figure 3-8.  Clinical scenario IMRT plan (left panel) and plan with rails out (right panel) for patient 3 with 
prostate shown in blue colorwash 
 
Figure 3-9 below shows the isodose coverage of the prostate with the rails in; the 
prescription isodose line is no longer completely covering the prostate as it was in the 
clinical scenario plan.  This ‘breaking’ of the prescription isodose line is less drastic than it 
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was for the rails out configuration (Figure 3-8), but may still not be clinically acceptable for 
plan approval.   
 
Figure 3-9.  Clinical scenario IMRT plan (left panel) and plan with rails in (right panel) for patient 3 with 
prostate shown in blue colorwash 
 
Figure 3-10 below shows the isodose coverage of the prostate with the imaging 
couch top only; the prescription isodose line is no longer completely covering the prostate as 
it was in the clinical scenario plan.  Again, this ‘breaking’ of the prescription isodose line 
may not be clinically acceptable for plan approval.   
 
Figure 3-10.  Clinical scenario IMRT plan (left panel) and plan with imaging couch only (right panel) for 
patient 3 with prostate shown in blue colorwash 
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3.2.4 IMRT Sample Plan Subtractions 
The same patient plans displayed in section 3.2.3 are displayed below as plan 
subtractions in Figure 3-11 through Figure 3-13 to show areas of dose loss between the 
clinical scenario and plans that include the couch and rails.  The figures represent the spatial 
areas and magnitudes of dose loss between the clinical scenario and the plans that account 
for various components and configurations of the couch and rails.  For all the subtractions 
shown, the red isodose line represents a loss of 110 cGy and each subsequent line represents 
5 cGy less than the previous line, ending with the navy blue line representing a dose loss of 
80 cGy.  Other representative plans are shown in the appendix. 
Figure 3-11 below shows a representative result for an IMRT plan subtraction 
between the rails out plan and the clinical scenario.  The path of the dose loss appears to be 
along the path of the posterior beams in the 8-field beam arrangement shown in Figure 2-2 
in section 2.2.1, and encompasses the entire volume of the prostate target. 
 
Figure 3-11.  Clinical scenario IMRT plan subtracted from rails out plan for patient 3 with prostate shown in 
blue colorwash  
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Figure 3-12 below shows a representative result for an IMRT plan subtraction 
between the rails in plan and the clinical scenario.  The path of the dose loss again follows 
the path of the posterior beams in the 8-field beam arrangement shown in Figure 2-1 in 
section 2.2.1, and again encompasses the entire volume of the prostate on this CT slice. 
However, the doss loss has a different pattern and magnitude of as compared to the previous 
figure for the rails out plan.  This is expected because the rails are not traversed by either of 
the posterior beams in our standard beam arrangement; only the couch top is intersected for 
the posterior fields as shown in Figure 2-2 in section 2.2.1. 
 
Figure 3-12.  Clinical scenario IMRT plan subtracted from rails in plan for patient 3 with prostate shown in 
blue colorwash 
 
Figure 3-13 below shows a representative result for an IMRT plan subtraction 
between the imaging couch top only plan and the clinical scenario.  The dose loss is the 
same in appearance as the rails-in subtraction in the previous figure.  This is expected 
because only the couch top is intersected for the posterior fields with the rails in as shown in 
Figure 2-2 in section 2.2.1. 
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Figure 3-13.  Clinical scenario IMRT plan subtracted from imaging couch top only plan for patient 3 with 
prostate shown in blue colorwash 
 
3.2.5 RapidArc DVH’s 
The DVH’s for each patient’s RapidArc plans (clinical scenario, rails out, rails in, 
imaging couch only) are displayed below.  They are displayed as relative structure volume 
versus absolute dose and the scale begins at 50 Gy (5000 cGy) for all the plans to better 
visualize the areas of difference between the plans.  A full view of the entire DVH’s for 
these plans can be seen in the appendix.  The PTV, prostate, rectum, and bladder are 
displayed in blue, red, green, and yellow in each figure, respectively.  Each clinical scenario 
plan, which is the outer most pair of prostate and PTV lines in each plan passed MDACC’s 
planning criteria of at least 98% coverage of the prostate and 95% coverage of the PTV by 
the prescription dose of 76 Gy.  The next pair of PTV and prostate DVH lines (shifted to the 
left and closest to the clinical scenario) are for the imaging couch top only for all patients 
and indicate that the couch top itself contributes to coverage loss to target structures.  The 
left-most two sets of prostate and PTV DVH lines (with the greatest reduction in coverage 
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from the clinical scenario) are for the plans with the rails out and rails in for all the patients.  
The rails out and rails in target DVH lines are very close and sometimes overlapping. This is 
reasonable because, as the beam arrangement shows in Figure 2-4 in section 2.2.2, both the 
couch top and rails are intersected during delivery in all rail configurations.  Figures 3.14 to 
3.18 indicate that both the imaging couch top and rails contribute to target dose loss. 
The effect to the critical structures is harder to visualize with this scale on the DVH’s 
and will be addressed separately in 3.6.3 Critical Structures: RapidArc.   
 
Figure 3-14.  DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for 
patient 1 structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and bladder 
are displayed in blue, red, green, and yellow, respectively. 
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Figure 3-15.  DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for 
patient 2 structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and bladder 
are displayed in blue, red, green, and yellow, respectively. 
 
Figure 3-16.  DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for 
patient 3 structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and bladder 
are displayed in blue, red, green, and yellow, respectively. 
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Figure 3-17.  DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for 
patient 4 structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and bladder 
are displayed in blue, red, green, and yellow, respectively. 
 
Figure 3-18.  DVH for all RapidArc plans (Clinical Scenario, Rails Out, Rails In, Imaging Couch Only) for 
patient 5 structures as a function of relative volume and absolute dose.  The PTV, prostate, rectum, and bladder 
are displayed in blue, red, green, and yellow, respectively. 
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3.2.6 RapidArc MU’s 
The MUs used for each patient RapidArc clinical scenario plan and all subsequent 
iterations of the plan including the couch top or rails are displayed below in Table 3-7 for 
each of the two fields with 30 and 330 degree collimator rotations.  The MUs for the clinical 
scenario plans were identical to subsequent iterations of the plans that included the couch 
and rails. 
Patient 
Collimator 
Rotation MU 
1 30 320 
1 330 343 
2 30 483 
2 330 430 
3 30 488 
3 330 480 
4 30 293 
4 330 284 
5 30 550  
5 330 613 
Table 3-7. The TPS optimized MU’s for the two arc fields for RapidArc plans 
 
 The MUs and normalization values for each patient’s plans are displayed below in 
Table 3-8 through Table 3-12. 
Patient 1     
Collimator 
Rotation 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
30 320 320 320 320 
330 343 343 343 343 
Plan 
Normalization: 
100% to 98% 
of PTV 100.0% 100.0% 100.0% 
Table 3-8.  MUs and normalization values for each plan iteration for patient 1 
45 
 
Patient 2     
Collimator 
Rotation 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
30 320 320 320 320 
330 343 343 343 343 
Plan 
Normalization: 
100% to 98% 
of PTV 100.0% 100.0% 100.0% 
Table 3-9.  MUs and normalization values for each plan iteration for patient 2 
Patient 3     
Collimator 
Rotation 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
30 320 320 320 320 
330 343 343 343 343 
Plan 
Normalization: 
100% to 95% 
of PTV 100.0% 100.0% 100.0% 
Table 3-10.  MUs and normalization values for each plan iteration for patient 3 
Patient 4     
Collimator 
Rotation 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
30 320 320 320 320 
330 343 343 343 343 
Plan 
Normalization: 
 100% to 98% 
of PTV 100.0% 100.0% 100.0% 
Table 3-11.  MUs and normalization values for each plan iteration for patient 4 
Patient 5     
Collimator 
Rotation 
Clinical 
Scenario MU 
Rails Out 
MU Rails In MU 
Imaging 
Couch Top 
Only MU 
30 320 320 320 320 
330 343 343 343 343 
Plan 
ormalization: 
100% to 98% 
of PTV  100.0% 100.0% 100.0% 
Table 3-12.  MUs and normalization values for each plan iteration for patient 5 
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3.2.7 RapidArc Sample Plans 
A sample patient clinical scenario RapidArc plan next its subsequent iterations (rails 
out, rails in, and couch top only plans) for the same CT slice are displayed below in Figure 
3-19 through Figure 3-21 for the same isodose lines.  The clinical scenario on the left panel 
of each figure shows complete coverage of the prostate (in blue colorwash) by the 76 Gy 
isodose line (in red), showing complete coverage of the structure on that CT slice when the 
couch and rails are not included in the plan, as is clinical practice at MDACC.  The image in 
the right panel show the changes in the prescription isodose coverage of the target when the 
couch and rails are considered.   Other representative plans are shown in the appendix.   
Figure 3-19 below shows the isodose coverage of the prostate with the rails out as 
compared to the coverage for the clinical scenario on the same CT slice; the prescription 
isodose line is no longer covering the prostate as it was in the clinical scenario plan.  This 
‘breaking’ of the prescription isodose line would not be clinically acceptable for plan 
approval.   
 
Figure 3-19.  Clinical scenario RapidArc plan (left panel) and rails out plan (right panel) for patient 3 with 
prostate shown in blue colorwash 
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Figure 3-20 below shows the isodose coverage of the prostate with the rails in as 
compared to the coverage for the clinical scenario on the same CT slice; the prescription 
isodose line is no longer covering the prostate as it was in the clinical scenario plan.  This 
‘breaking’ of the prescription isodose line is similar to the rails out configuration and would 
also not be clinically acceptable for plan approval.   
 
Figure 3-20.  Clinical scenario RapidArc plan (left panel) and rails in plan (right panel) for patient 3 with 
prostate shown in blue colorwash 
 
Figure 3-21 below shows the isodose coverage of the prostate with the imaging couch 
top only as compared to the coverage for the clinical scenario on the same CT slice; the 
prescription isodose line is no longer covering the prostate as it was in the clinical scenario 
plan.  This ‘breaking’ of the prescription isodose line is less than when the rails were also 
included and may not be clinically acceptable for plan approval.   
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Figure 3-21.  Clinical scenario RapidArc plan (left panel) and imaging couch only plan (right panel) for 
patient 3 with prostate shown in blue colorwash 
 
3.2.8 RapidArc Sample Plan Subtractions 
The same patient plans displayed in section 3.2.3 are displayed below as plan 
subtractions in Figure 3-22 through Figure 3-24 to show areas and magnitudes of dose loss 
between the clinical scenario and plans that include the couch and rails.  For all the 
subtractions shown, the red isodose line represents a loss of 110 cGy and each subsequent 
line represents 5 cGy less than the previous line, ending with the navy blue line representing 
a dose loss of 80 cGy.  Other representative plans are shown in the appendix. 
Figure 3-22 below shows a representative result for a RapidArc plan subtraction 
between the rails out plan and the clinical scenario.  The path of the dose loss is along the 
length of the couch and not as narrow as the IMRT plan subtraction in Figure 3-11 in section 
3.2.4 because the delivery of dose is continuous during RapidArc delivery for all gantry 
angles and not fixed as in IMRT.  The area of dose loss encompasses the entire volume of 
the prostate target and has the largest magnitude along the path of the rails. 
 
49 
 
 
Figure 3-22.  Clinical scenario RapidArc plan subtracted from rails out plan for patient 3 with prostate shown 
in blue colorwash  
 
Figure 3-23 below shows a representative result for a RapidArc plan subtraction 
between the rails in plan and the clinical scenario.  The pattern of dose loss is also spatially 
different from the rails out subtraction shown in the previous figure and is due to the 
differing rail position.  The area of dose loss encompasses the entire volume of the prostate 
target has the largest magnitude along the path of the rails. 
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Figure 3-23.  Clinical scenario RapidArc plan subtracted from rails in plan for patient 3 with prostate shown in 
blue colorwash 
 
Figure 3-24 below shows a representative result for a RapidArc plan subtraction 
between the imaging couch top only plan and the clinical scenario.  The pattern of dose loss 
is also spatially different from both the rails out and rails in subtraction shown in the two 
previous figures and shows only the dose lose contribution from the couch top.  The area of 
dose loss encompasses the entire volume of the prostate target. 
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Figure 3-24.  Clinical scenario RapidArc plan subtracted from the imaging couch top only plan for patient 3 
with prostate shown in blue colorwash 
 
3.3 Dosimetric Accuracy Evaluation 
3.3.1 Absolute Point Dose Analysis: TPS Couch Model Validation 
The results for the first goal of specific aim 2, to evaluate the ability of the Eclipse 
TPS to predict the dose perturbation caused by the couch and rails, are shown below in 
Table 3-13 and Table 3-14 for all of the IMRT and RapidArc plans.  
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Patient Plan Delivery 
Predicted Dose 
(Hybrid Plan) (cGy) 
Measured Dose 
(cGy) % Difference 
1 IMRT--Rails Out 221.8 220.8 0.5% 
2 IMRT--Rails Out 214.0 211.9 1.0% 
3 IMRT--Rails Out 199.2 199.4 0.1% 
4 IMRT--Rails Out 203.3 201.4 1.0% 
5 IMRT--Rails Out 238.8 237.7 0.5% 
1 IMRT--Rails In 226.5 226.1 0.2% 
2 IMRT--Rails In 219.4 218.9 0.2% 
3 IMRT--Rails In 204.2 205.2 0.5% 
4 IMRT--Rails In 209.7 210.8 0.5% 
5 IMRT--Rails In 244.0 244.9 0.4% 
 Table 3-13.  TPS-calculated dose for IMRT plans including the couch and rails compared to the measured 
dose for specified plan delivery. 
Patient Plan Delivery 
Predicted Dose 
(Hybrid Plan) (cGy) 
Measured Dose 
(cGy) % Difference 
1 Rapid Arc--Rails Out 218.0 218.4 0.2% 
2 Rapid Arc--Rails Out 215.0 211.2 1.8% 
3 Rapid Arc--Rails Out 201.2 200.6 0.3% 
4 Rapid Arc--Rails Out 199.8 202.5 1.3% 
5 Rapid Arc--Rails Out 235.3 235.5 0.1% 
1 Rapid Arc--Rails In 218.6 219.1 0.2% 
2 Rapid Arc--Rails In 215.8 219.5 1.7% 
3 Rapid Arc--Rails In 203.9 202.8 0.5% 
4 Rapid Arc--Rails In 201.3 203.1 0.9% 
5 Rapid Arc--Rails In 235.2 234.4 0.3% 
Table 3-14.  TPS-calculated dose for RapidArc plans including the couch and rails compared to the actual 
measured dose for specified plan delivery. 
 
The average percent difference between absolute point dose measurements and TPS 
hybrid calculations including the couch and rails was 0.6% and 0.4% for IMRT with the 
rails out and rails in, respectively.  The average percent difference between absolute point 
dose measurements and TPS hybrid calculations including the couch and rails was 0.7% for 
RapidArc with the rails out and rails in.  
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3.3.2 Absolute Point Dose Analysis: Clinical QA Experience 
The results for the second goal of specific aim 2, to evaluate the difference in dose 
between measurements taken with the couch and rails in the IMRT QA phantom to the 
absolute dose predicted by the Eclipse TPS when the couch and rails are not taken into 
account, are shown in Table 3-15 and Table 3-16, for all IMRT and RapidArc plan 
deliveries. These results reflect the difference between what we think is being delivered and 
what we are delivering during our IMRT QA.   
Patient Plan Delivery 
Predicted Dose 
(Clinical Scenario) 
(cGy) 
Measured Dose 
(cGy) % Difference 
1 IMRT--Rails Out 230.0 220.8 4.1% 
2 IMRT--Rails Out 223.2 212.7 4.8% 
3 IMRT--Rails Out 209.5 199.4 5.0% 
4 IMRT--Rails Out 214.2 201.4 6.2% 
5 IMRT--Rails Out 247.8 237.7 4.2% 
1 IMRT--Rails In 230.0 226.1 1.7% 
2 IMRT--Rails In 223.2 218.9 2.0% 
3 IMRT--Rails In 209.5 205.2 2.1% 
4 IMRT--Rails In 214.2 210.8 1.6% 
5 IMRT--Rails In 247.8 244.9 1.2% 
Table 3-15.  TPS-calculated dose for IMRT plans not accounting for the couch and rails (clinical scenario) 
compared to the measured dose with the couch and rails 
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Patient Plan Delivery 
Predicted Dose 
(Clinical Scenario) 
(cGy) 
Measured Dose 
(cGy) % Difference 
1 Rapid Arc--Rails Out 218.4 223.8 2.4% 
2 Rapid Arc--Rails Out 215.0 221.2 2.8% 
3 Rapid Arc--Rails Out 200.6 209.8 4.5% 
4 Rapid Arc--Rails Out 202.5 208.2 2.8% 
5 Rapid Arc--Rails Out 235.5 242.2 2.8% 
1 Rapid Arc--Rails In 219.1 223.8 2.1% 
2 Rapid Arc--Rails In 215.8 221.2 2.5% 
3 Rapid Arc--Rails In 202.8 209.8 3.4% 
4 Rapid Arc--Rails In 203.1 208.2 2.5% 
5 Rapid Arc--Rails In 234.4 242.2 3.3% 
Table 3-16.  TPS-calculated dose for RapidArc plans not accounting for the couch and rails (clinical scenario) 
compared to the measured dose with the couch and rails 
 
The average percent difference between absolute point dose measurements including 
the couch and rails and TPS hybrid calculations neglecting the couch and rails was 4.7% and 
1.7% for IMRT with the rails out and rails in, respectively.  The average percent difference 
between absolute point dose measurements and TPS hybrid calculations was 3.0% and 2.7% 
for RapidArc with the rails out and rails in, respectively.      
The agreement was better on average and for each plan when the treatment couch 
and rails were included in TPS hybrid calculations as shown below in 3-17.   Most 
importantly to note, all of the IMRT and RapidArc plans with the rails out would fail 
MDACC’s IMRT QA passing criteria of + 3% agreement.  
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Treatment modality 
and configuration 
Difference including 
couch and rails 
Difference excluding couch 
and rails (clinical scenario) 
IMRT    
Rails out 0.6% 4.8% 
Rails in 0.4% 1.7% 
RapidArc    
Rails out 0.7% 3.1% 
Rails in 0.7% 2.7% 
3-17. Average percentage differences between measured point doses and TPS-calculated point doses for hybrid 
plans that included the couch and rails and plans that did not include these structures per normal IMRT QA 
protocol. 
 
3.4 DVH Analysis: IMRT 
3.4.1 Volume Coverage to Prostate and PTV: IMRT 
 DVH analysis to evaluate the relative volume coverage of the prostate and PTV 
target structures was performed using the DVH for each patient plan.  Table 3-18 shows 
target coverage for the clinical scenario plan.  Target coverage for the plans with the rails 
out, rails in, and imaging couch top only are shown in Table 3-19, through Table 3-21, 
respectively. Lastly, Table 3-22 shows the average of the target coverage over all patients 
for all the plan scenarios displayed in the preceding tables. 
Clinical Scenario       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx 
Dose 100% 100% 100% 100% 100% 
PTV % Volume Coverage at Rx 
Dose 98% 96% 96% 96% 97% 
Table 3-18.  Percent coverage of target structures for clinically optimized IMRT plans for each patient at 
prescription dose of 76Gy 
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Rails Out       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx 
Dose 80% 54% 6% 35% 3% 
PTV % Volume Coverage at Rx 
Dose 77% 50% 17% 42% 11% 
Table 3-19.  Percent coverage of target structures for rails out IMRT plans at prescription dose of 76Gy 
Rails In       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx 
Dose 100% 80% 76% 99% 62% 
PTV % Volume Coverage at Rx 
Dose 95% 77% 71% 89% 64% 
Table 3-20.  Percent coverage of target structures for rails in IMRT plans at prescription dose of 76Gy 
Imaging Couch Top       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx 
Dose 100% 80% 77% 99% 62% 
PTV % Volume Coverage at Rx 
Dose 95% 77% 72% 89% 64% 
Table 3-21.  Percent coverage of target structures for imaging couch top only IMRT plans at prescription dose 
of 76Gy 
Plan Type: 
Clinical 
Scenario  Rails Out Rails In 
Imaging Couch Top 
Only 
Prostate Average % Volume 
Coverage at Rx Dose 100% 35% 84% 84% 
PTV Average % Volume 
Coverage at Rx Dose 97% 39% 79% 79% 
Table 3-22.  Average relative volume coverage at prescription dose of 76 Gy to prostate and PTV target 
structures for IMRT Plans with varying rail configurations 
 
All of the clinical scenario plans met MDACC clinical approval criteria of 98% 
coverage of the prostate and 95% of the PTV being covered by the prescription dose of 
76Gy with an average of 100% coverage of the prostate and 97% coverage of the PTV at the 
prescription dose of 76 Gy.  The presence of the couch top and rails in vary configurations 
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causes a loss in coverage that is, on average, unacceptable for plan approval.  The individual 
magnitudes of coverage loss for each of the five patients individually vary widely due to 
differences in MU’s, patient size, and volume of target structures, which is expected in a 
random patient population.              
3.4.2 Dose Loss to Prostate and PTV: IMRT 
The minimum, maximum, and mean dose loss to the target prostate and PTV 
structures were obtained from the DVH data.  The minimum, maximum, and mean doses to 
the target structures in the plans with the couch and rails in varying configurations were 
subtracted from the respective clinical scenario plans to obtain the absolute dose losses.  
These values are displayed as the percentage of prescribed dose loss to the targets (76 Gy).  
The dose losses for the rails out, rails in, and couch top only plans for all IMRT patients are 
shown in Table 3-23, Table 3-24, and Table 3-25, respectively.  Lastly, Table 3-26 shows 
the average of the dose losses for all patients and plan types.   
Rails Out      
Patient 1 2 3 4 5 
Prostate Min Dose Loss (%) 4.9% 3.6% 5.2% 4.9% 4.3% 
Prostate Max Dose Loss (%) 4.2% 2.8% 4.3% 3.2% 3.2% 
Prostate Mean Dose Loss (%) 4.3% 3.7% 5.1% 4.1% 3.9% 
PTV Min Dose Loss (%) 3.6% 3.1% 5.8% 4.4% 3.6% 
PTV Max Dose Loss (%) 3.6% 2.7% 4.6% 3.4% 3.0% 
PTV Mean Dose Loss (%) 4.1% 3.7% 4.9% 3.9% 3.7% 
Table 3-23.  Minimum, maximum, and mean prescription dose loss between the clinical scenario and rails out 
plans for all IMRT patients’ target structures 
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Rails In      
Patient 1 2 3 4 5 
Prostate Min Dose Loss (%) 1.8% 1.5% 2.8% 1.9% 1.6% 
Prostate Max Dose Loss (%) 1.6% 1.4% 2.8% 1.6% 1.6% 
Prostate Mean Dose Loss (%) 1.7% 1.6% 2.8% 1.9% 1.7% 
PTV Min Dose Loss (%) 0.9% 1.6% 2.6% 1.2% 1.5% 
PTV Max Dose Loss (%) 1.9% 1.4% 2.9% 1.6% 1.5% 
PTV Mean Dose Loss (%) 1.7% 1.7% 2.8% 1.8% 1.6% 
Table 3-24. Minimum, maximum, and mean prescription dose loss between the clinical scenario and rails in 
plans for all IMRT patients’ target structures 
Imaging Couch Top      
Patient 1 2 3 4 5 
Prostate Min Dose Loss (%) 1.8% 1.5% 2.8% 1.9% 1.6% 
Prostate Max Dose Loss (%) 1.6% 1.4% 2.8% 1.6% 1.6% 
Prostate Mean Dose Loss (%) 1.7% 1.6% 2.8% 1.9% 1.7% 
PTV Min Dose Loss (%) 0.9% 1.6% 2.6% 1.2% 1.5% 
PTV Max Dose Loss (%) 1.9% 1.4% 2.9% 1.6% 1.5% 
PTV Mean Dose Loss (%) 1.7% 1.7% 2.8% 1.8% 1.6% 
Table 3-25. Minimum, maximum, and mean prescription dose loss between the clinical scenario and imaging 
couch top only plans for all IMRT patients’ target structures 
 
   
Plan Type: Rails Out Rails In 
Imaging Couch 
Top Only 
Average Prostate Min Dose Loss (%) 4.6% 1.9% 1.9% 
Average Prostate Max Dose Loss (%) 3.5% 1.8% 1.8% 
Average Prostate Mean Dose Loss (%) 4.2% 2.0% 2.0% 
Average PTV Min Dose Loss (%) 4.1% 1.6% 1.5% 
Average PTV Max Dose Loss (%) 3.5% 1.9% 1.9% 
Average PTV Mean Dose Loss (%) 4.1% 1.9% 1.9% 
Table 3-26. Average prescription dose loss between the clinical scenario and plans with rails out, rails in, and 
imaging couch top only for IMRT 
 
 On average, the dose loss to the prostate and PTV was greater for IMRT with the 
rails out (typically 4%) than for rails in or the couch top alone (typically 2%).  This is 
expected because the rails are only traversed by the posterior fields when the rails are in the 
out position.  The average dose loss for the plans with the rails in is the same as for the 
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couch top only; this is consistent with the DVH figures and plan subtractions in sections 
3.2.1 and 3.2.4, respectively. 
3.4.3 Critical Structures: IMRT 
The results of analysis on the normal tissue structure volume of the rectum and 
bladder receiving doses that are used as DVH constraints for treatment planning were 
obtained from IMRT DVH information.  Table 3-27 shows the critical structure volume-
dose information for all IMRT patients’ clinical scenario plans.  The critical structure 
volume-dose information for all IMRT patients’ rails out, tails in, and couch top only plans 
are shown in Table 3-28, Table 3-29, and Table 3-30, respectively. Lastly, Table 3-31 shows 
the average volume-dose data for all patients and plans.   
  
Clinical 
Scenario Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Rectum 40 Gy<60% 44% 58% 40% 41% 45% 
  45 Gy<50% 39% 48% 35% 31% 37% 
  60 Gy<40% 25% 24% 23% 15% 20% 
  70 Gy<20% 17% 15% 14% 9% 11% 
  75.6 Gy<15% 12% 8% 5% 6% 5% 
  78-80 Gy <5% 6% 0% 0% 0% 0% 
Bladder 70 Gy<20% 5% 21% 13% 11% 10% 
Table 3-27.  Dose-volume data for each IMRT clinical scenario plan as a function of clinical DVH dose-
volume constraints  
  Rails Out Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Rectum 40 Gy<60% 42% 54% 38% 38% 41% 
  45 Gy<50% 37% 43% 33% 29% 33% 
  60 Gy<40% 23% 21% 21% 13% 18% 
  70 Gy<20% 14% 12% 9% 8% 7% 
  75.6 Gy<15% 6% 12% 0% 3% 0% 
  78-80 Gy <5% 0% 0% 0% 0% 0% 
Bladder 70 Gy<20% 5% 19% 11% 10% 9% 
Table 3-28.   Dose-volume data for each IMRT rails out plan as a function of clinical DVH dose-volume 
constraints 
60 
 
 
  Rails In  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Rectum 40 Gy<60% 43% 56% 39% 39% 43% 
  45 Gy<50% 38% 46% 33% 30% 35% 
  60 Gy<40% 24% 23% 21% 14% 19% 
  70 Gy<20% 16% 13% 11% 8% 9% 
  75.6 Gy<15% 10% 5% 1% 4% 3% 
  78-80 Gy <5% 0% 0% 0% 0% 0% 
Bladder 70 Gy<20% 5% 20% 12% 10% 10% 
Table 3-29.  Dose-volume data for each IMRT rails in plan as a function of clinical DVH dose-volume 
constraints 
  
Imaging Couch 
Top Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Rectum 40 Gy<60% 43% 56% 39% 39% 43% 
  45 Gy<50% 38% 46% 33% 30% 35% 
  60 Gy<40% 24% 23% 22% 14% 19% 
  70 Gy<20% 16% 14% 11% 8% 9% 
  75.6 Gy<15% 10% 5% 1% 4% 3% 
  78-80 Gy <5% 0% 0% 0% 0% 0% 
Bladder 70 Gy<20% 5% 20% 12% 10% 10% 
Table 3-30.   Dose-volume data for each IMRT imaging couch top only plan as a function of clinical DVH 
dose-volume constraints 
 Averages 
Clinical 
Scenario 
Couch with 
Rails Out 
Couch with 
Rails In 
Imaging 
Couch Top 
Only 
Rectum 40 Gy<60% 45% 42% 44% 44% 
  45 Gy<50% 38% 35% 36% 36% 
  60 Gy<40% 21% 19% 20% 20% 
  70 Gy<20% 13% 10% 12% 12% 
  75.6 Gy<15% 7% 4% 4% 4% 
  78-80 Gy <5% 1% 0% 0% 0% 
Bladder 70 Gy<20% 12% 11% 11% 11% 
Table 3-31.  Averaged dose-volume data for all IMRT plan iterations as a function of clinical DVH dose-
volume constraints 
 
 On average, the rectum and bladder received less dose to their volumes when the 
imaging couch top and/or rails were included in the plans.  This indicates that when the 
couch and rails are not included in treatment planning, the critical structures are receiving 
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less dose than indicated by the clinical scenario which could have implications about the 
validity of the current clinical DVH constraints that will discussed in the next chapter.   
3.5 Tumor Control Probability: IMRT 
3.5.1 TCP Results: IMRT 
The DVH information from each IMRT patient’s plans (clinical scenario, rails out, 
and rails in) was used along with the specific input parameters mentioned in section 2.5.1 for 
the TCP model.  Values for the imaging couch top only plan were not calculated as they 
would be the same as the rails in plan.  The results are shown below for all patients in Table 
3-32 and averaged over all patients in Table 3-33.     
IMRT TCP 
Clinical 
Scenario Rails Out Rails In 
Patient 1 92% 85% 90% 
Patient 2 89% 84% 86% 
Patient 3 90% 80% 85% 
Patient 4 91% 83% 88% 
Patient 5 88% 79% 85% 
Table 3-32.  IMRT TCP results for each patient’s clinical scenario, rails out, and rails in plans 
 
  
Clinical 
Scenario Rails Out Rails In 
IMRT TCP 90% 82% 87% 
Table 3-33.  IMRT TCP results averaged over all patients 
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The IMRT TCP results show a reduction in predicted tumor control due to the 
attenuation of the couch top and rails not being accounted for in treatment planning. While 
clinically it is believed that 90% of patient tumors would be controlled with the developed 
treatment plans, in fact, because less dose is being delivered, only 82% (rails out) or 87% 
(rails in) of tumors would be controlled.  The TCP reduction for each patient’s rails out 
plans was greater than the loss predicted by the respective rails in plan.  This trend is 
consistent with the magnitudes of dose and volume loss shown in 3.4.1 and 3.4.2; 
specifically that the rails out plans always had greater losses in mean dose and coverage to 
the targets than the respective rails in plans.    
3.6 DVH Analysis: RapidArc     
3.6.1 Volume Coverage to Prostate and PTV: RapidArc 
Similar to 3.4.1, the loss of target coverage was examined for RapidArc plans. The 
results are shown below for the clinical scenario in Table 3-34.  The results for the rails out, 
rails in, and couch top only plans are shown in Table 3-35, Table 3-36, and Table 3-37, 
respectively.  Lastly, Table 3-38 shows the average target coverage losses for all RapidArc 
plans and patients. 
Clinical Plan       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx 
Dose 98% 99% 100% 99% 98% 
PTV % Volume Coverage at Rx 
Dose 98% 98% 95% 98% 98% 
Table 3-34. Percent prescription dose coverage of target structures for clinically optimized RapidArc plans 
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Rails Out       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx 
Dose 6% 30% 28% 24% 3% 
PTV % Volume Coverage at Rx 
Dose 39% 46% 26% 5% 21% 
Table 3-35. Percent prescription dose coverage of target structures for rails out RapidArc plans 
Rails In       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx 
Dose 3% 28% 47% 1% 4% 
PTV % Volume Coverage at Rx 
Dose 29% 40% 31% 10% 22% 
Table 3-36.   Percent prescription dose coverage of target structures for rails in RapidArc plans 
Imaging Couch Top       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx 
Dose 37% 55% 75% 9% 24% 
PTV % Volume Coverage at Rx 
Dose 68% 72% 63% 27% 53% 
Table 3-37. Percent prescription dose coverage of target structures for imaging couch top only RapidArc plans 
 
Plan Type: 
Clinical 
Scenario 
Couch with 
Rails Out 
Couch with 
Rails In 
Couch Top 
Only 
Prostate Average % Volume 
Coverage at Rx Dose 99% 18% 17% 40% 
PTV Average % Volume 
Coverage at Rx Dose 97% 27% 26% 57% 
Table 3-38.   Average relative volume coverage at prescription dose of 76 Gy to prostate and PTV target 
structures for RapidArc Plans with varying rail configurations 
 
All of the clinical scenario plans met MDACC clinical approval criteria of 98% of 
the prostate and 95% of the PTV being covered by the prescription dose of 76Gy with an 
average of 99% coverage of the prostate and 97% coverage of the PTV.  For all the plans 
that included the couch and rails, the target coverage loss was substantial enough to cause a 
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failure of clinical planning criteria.  Similar losses in coverage for the rails out and rails in 
plans were observed which was expected based on the DVH results shown previously. The 
loss in coverage varied greatly between the five patients due to differences in MU’s, patient 
size, and volume of target structures, which is expected in a random patient population.      
3.6.2 Dose Loss to Prostate and PTV: RapidArc 
Similar to section 3.4.2, the percentage of prescription dose lost for the PTV and 
prostate target structures is shown for the RapidArc plans.  Minimum, maximum, and mean 
dose losses to the targets for the rails out, rails in, and couch top only plans for all patients 
are shown in Table 3-39, Table 3-40, and Table 3-41, respectively.  Lastly, Table 3-42 
shows the average dose losses for all plans from the preceding tables.  
Rails Out      
Patient 1 2 3 4 5 
Prostate Min Dose Loss (%) 3.0% 2.6% 4.6% 3.8% 3.5% 
Prostate Max Dose Loss (%) 2.5% 1.5% 3.5% 2.9% 2.7% 
Prostate Mean Dose Loss (%) 2.5% 2.3% 4.0% 3.6% 3.5% 
PTV Min Dose Loss (%) 3.0% 3.3% 4.3% 4.1% 3.4% 
PTV Max Dose Loss (%) 2.2% 1.9% 2.7% 2.6% 2.3% 
PTV Mean Dose Loss (%) 2.5% 2.5% 3.9% 3.5% 3.4% 
Table 3-39.  Minimum, maximum, and mean prescription dose loss between the clinical scenario and rails out 
plans for RapidArc patients’ target structures 
 
Rails In      
Patient 1 2 3 4 5 
Prostate Min Dose Loss (%) 3.1% 2.6% 4.3% 3.4% 3.9% 
Prostate Max Dose Loss (%) 2.6% 1.6% 2.9% 2.4% 2.8% 
Prostate Mean Dose Loss (%) 2.7% 2.2% 3.4% 3.1% 3.3% 
PTV Min Dose Loss (%) 3.1% 2.7% 4.2% 3.4% 3.2% 
PTV Max Dose Loss (%) 2.2% 2.2% 2.6% 2.2% 2.2% 
PTV Mean Dose Loss (%) 2.8% 2.6% 3.7% 3.1% 3.2% 
Table 3-40.  Minimum, maximum, and mean prescription dose loss between the clinical scenario and rails in 
plans for RapidArc patients’ target structures 
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Imaging Couch Top      
Patient 1 2 3 4 5 
Prostate Min Dose Loss (%) 1.9% 1.6% 2.9% 2.3% 2.2% 
Prostate Max Dose Loss (%) 1.7% 2.6% 2.6% 1.8% 1.8% 
Prostate Mean Dose Loss (%) 1.7% 1.6% 2.5% 2.2% 2.2% 
PTV Min Dose Loss (%) 1.9% 2.3% 2.8% 2.6% 2.3% 
PTV Max Dose Loss (%) 1.5% 1.3% 1.9% 1.7% 1.5% 
PTV Mean Dose Loss (%) 1.7% 1.7% 2.6% 2.2% 2.1% 
Table 3-41.  Minimum, maximum, and mean prescription dose loss between the clinical scenario and imaging 
couch top only plans for RapidArc patients’ target structures 
 
Averages    
Plan Type: Rails Out Rails In 
Imaging Couch 
Top Only 
Average Prostate Min Dose Loss (%) 3.5% 3.5% 2.2% 
Average Prostate Max Dose Loss (%) 2.6% 2.5% 2.1% 
Average Prostate Mean Dose Loss (%) 3.2% 2.9% 2.0% 
Average PTV Min Dose Loss (%) 3.6% 3.3% 2.4% 
Average PTV Max Dose Loss (%) 2.3% 2.3% 1.6% 
Average PTV Mean Dose Loss (%) 3.2% 3.1% 2.1% 
Table 3-42. Average prescription dose loss between the clinical scenario and plans with rails out, rails in, and 
imaging couch top only for RapidArc patients’ target structures 
  
On average, the mean dose loss to the prostate and PTV was comparable for 
RapidArc with the rails out and the rails in, typically around 3%.  This is expected because 
both the couch top and rails are traversed regardless of rail position with the arc field 
arrangement as shown in Figure 2-4.  On average, the majority of the dose loss is associated 
with the imaging couch only, and less contribution is from the rails. This is unlike the IMRT 
plans in which the rails contributed the most to dose loss.  This is expected because the 
couch top is continuously traversed through the posterior fields during RapidArc instead of 
at only two beam positions as with the IMRT beam arrangement used.   
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The dose losses to the targets for RapidArc were, on average, less than the losses 
observed with the rails out for IMRT and more than the losses with the rails in for IMRT.  
The dose loss due to the couch top alone was the same, on average, within 0.2% for 
RapidArc and IMRT.  The same order was not observed for coverage losses to the targets 
for RapidArc and IMRT.  All couch and rail configurations (rails out, rails in, and couch top 
only) demonstrated greater loss in target coverage with RapidArc compared to IMRT.       
 
3.6.3 Critical Structures: RapidArc 
Similar to 3.4.3, the volume of normal tissue structures receiving doses that are 
assessed during treatment planning were analyzed with the RapidArc plan DVH’s.  The 
dose-volume information for the clinical scenario plans is shown in Table 3-43.  The dose-
volume information for the rails out, rails in, and couch top only plans are shown in Table 
3-44, Table 3-45, and Table 3-46, respectively.  A summary of the average dose-volume 
information across all patients and plans is shown in Table 3-47.  
  
Clinical 
Scenario Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Rectum 40 Gy<60% 51% 38% 41% 44% 17% 
  45 Gy<50% 45% 33% 32% 36% 15% 
  60 Gy<40% 24% 20% 17% 20% 9% 
  70 Gy<20% 13% 12% 10% 13% 6% 
  75.6 Gy<15% 7% 7% 4% 6% 3% 
  78-80 Gy <5% 0% 0% 0% 0% 0% 
Bladder 70 Gy<20% 8% 19% 10% 12% 11% 
Table 3-43. Dose-volume data for each RapidArc clinical scenario plan as a function of clinical DVH dose-
volume constraints 
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  Rails Out Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Rectum 40 Gy<60% 50% 37% 38% 41% 17% 
  45 Gy<50% 43% 31% 29% 33% 14% 
  60 Gy<40% 22% 18% 15% 18% 8% 
  70 Gy<20% 11% 11% 7% 10% 5% 
  75.6 Gy<15% 2% 1% 0% 0% 1% 
  78-80 Gy <5% 0% 0% 0% 0% 0% 
Bladder 70 Gy<20% 7% 17% 9% 11% 10% 
Table 3-44.  Dose-volume data for each RapidArc rails out plan as a function of clinical DVH dose-volume 
constraints 
  Rails In  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Rectum 40 Gy<60% 49% 36% 37% 41% 16% 
  45 Gy<50% 42% 31% 29% 33% 14% 
  60 Gy<40% 22% 18% 15% 18% 8% 
  70 Gy<20% 11% 11% 7% 10% 5% 
  75.6 Gy<15% 2% 2% 0% 0% 1% 
  78-80 Gy <5% 0% 0% 0% 0% 0% 
Bladder 70 Gy<20% 7% 17% 9% 11% 10% 
Table 3-45.  Dose-volume data for each RapidArc rails in plan as a function of clinical DVH dose-volume 
constraints 
  
Imaging Couch 
Top Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Rectum 40 Gy<60% 50% 37% 38% 42% 17% 
  45 Gy<50% 43% 32% 30% 34% 14% 
  60 Gy<40% 23% 19% 16% 19% 9% 
  70 Gy<20% 12% 11% 8% 11% 5% 
  75.6 Gy<15% 5% 4% 1% 0% 2% 
  78-80 Gy <5% 0% 0% 0% 0% 0% 
Bladder 70 Gy<20% 7% 18% 10% 12% 10% 
Table 3-46.  Dose-volume data for each RapidArc imaging couch top only plan as a function of clinical DVH 
dose-volume constraints 
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  Averages  
Clinical 
Scenario 
Couch 
with Rails 
Out 
Couch 
with Rails 
In 
Imaging 
Couch 
Top Only 
Rectum 40 Gy<60% 38% 36% 36% 37% 
  45 Gy<50% 32% 30% 30% 31% 
  60 Gy<40% 18% 16% 16% 17% 
  70 Gy<20% 11% 9% 9% 9% 
  75.6 Gy<15% 5% 1% 1% 2% 
  78-80 Gy <5% 0% 0% 0% 0% 
Bladder 70 Gy<20% 12% 11% 11% 11% 
Table 3-47.  Average dose-volume data for all plan iterations as a function of clinical DVH dose-volume 
constraints 
On average, the rectum and bladder received less dose to their volumes when the 
imaging couch top and/or rails were included in the plans.  This indicates that when the 
couch and rails are not included in treatment planning, the critical structures are receiving 
less dose than indicated by the clinical scenario. 
3.7 Tumor Control Probability: RapidArc 
3.7.1 TCP Results: RapidArc 
The DVH information from each RapidArc patient’s plans (clinical scenario, rails 
out, and rails in) was used along with the specific input parameters mentioned in section 
2.5.1 for the TCP model.  Values for the imaging couch top only plan were not calculated as 
this does not represent a clinically deliverable plan for RapidArc.  The results are shown 
below for all patients in 3-48 and averaged over all patients in 3-49.   
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RapidArc 
TCP 
Clinical 
Scenario 
Rails 
Out Rails In 
Patient 1 87% 81% 81% 
Patient 2 87% 82% 82% 
Patient 3 90% 82% 83% 
Patient 4 87% 78% 79% 
Patient 5 87% 79% 80% 
3-48.  RapidArc TCP results for each patient’s clinical scenario, rails out, and rails in plans 
 
  
Clinical 
Scenario 
Rails 
Out 
Rails 
In 
RapidArc TCP 88% 81% 81% 
3-49.  RapidArc TCP results averaged over all patients 
 
The RapidArc TCP results show a reduction in predicted tumor control due to the 
attenuation of the couch top and rails not being accounted for in treatment planning. While 
clinically it is believed that 88% of patient tumors would be controlled with the developed 
treatment plans, in fact, because less dose is actually being delivered, only 81% of tumors 
would be controlled.  The TCP reduction for each patient’s rails out and rails in plan were 
the same.  This trend is consistent with the magnitudes of dose and volume loss shown in 
3.6.1 and 3.6.2; specifically that both the rails out and rails in plans, on average, had similar 
dose and volume coverage losses to the targets.   
70 
 
Chapter 4 Discussion 
4.1 General Discussion 
4.1.1 Specific Aim 1  
 Our results for specific aim 1 looked at the relative attenuation of the imaging couch 
top, mesh couch top, and rails of the Varian Exact Couch, as shown in the results in Chapter 
3, section 1. They indicate three things: first, that the rails demonstrate a large amount of 
beam attenuation when traversed, secondly, that there is a measurable contribution of the 
imaging couch top to the attenuation, and thirdly, that the amount of attenuation has an 
angular dependency.  This aim was meant to establish that our couch components do cause 
attenuation that could lead to dosimetric impact and to confirm that the magnitude of 
attenuation was similar to that of other published results.  
The results in Table 3-1 show that when the rails are in the out position, attenuation 
occurs due to intersection with the couch top and rails from 115-135 degrees and, 
symmetrically, from 225-245 degrees of gantry rotation with the greatest attenuation of the 
beam at 120 and 240 regardless of which couch top was used.  When the rails were in, the 
angles of intersection were from 160 to 205 degrees excluding 180 degrees where there is a 
gap between the two rails.  The findings that these gantry angles are problematic for couch-
rail-beam intersection are consistent with the study by Wagner et al that found attenuation 
for similar gantry angles on the Varian Exact Couch (20).   The magnitude of this maximum 
attenuation was larger than 20% when both the rails and imaging couch were traversed and 
more than 17% when the rails and mesh tops were traversed in the out position.  With the 
rails in and the imaging couch top, the magnitude of the attenuation was as high as 14%.  
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These results are reasonably consistent with the literature that found up to 17% attenuation 
for a variety of couches and rails (12,13,14).     
The 3% difference between the maximum attenuation of the imaging couch top and 
mesh couch top with the rails out can attributed to the added attenuation that imaging couch 
top has.  The greater attenuating properities of the imaging couch versus the mesh couch top 
are illustrated in the third column of Table 3-1 and range from 3 to 5% greater attenuation 
by the imaging couch top alone.  This result is higher than the findings by Wagner et al who 
measured 1.49% - 3.20% attenuation of the imaging couch top (20).  This difference could 
be due to differences in material used for measurement; we used a 6-MV build up cap and 
Wagner et al used a cylindrical PMMA phantom.  Other explanations for the disagreement 
could be due to differences in linac machine output, positioning of the ion chamber, and 
measurement devices.  The varying attenuation as a function of beam angle can be attributed 
to possible heterogeneities in couch density, differing path lengths of material being 
trasversed by different gantry angles, and systematic positional errors in the ion chamber.  
An inconsistent difference between the mesh couch top and imaging couch top was shown 
in the results at 115 and 245 degrees, where the mesh top attenuates more than the imaging 
top [approximately 12% and 5%, respectively for both angles].  This could be attributed to 
positional uncertainity in the ion chamber caused when it had to be moved and repositioned 
after the mesh insert was added to the couch.  Another possibility is that the result is correct 
and due to the greater density of the mesh top on the edges than the rest of the couch top 
whereas the imaging top is fairly uniform in composition and density.   
72 
 
The angluar depedence on attenuation by the couch rails can be attributed to known 
intentional heterogeneity in the cabon fiber rails as modeled in the Eclipse TPS in Figure 
2-2.  The carbon fiber rails are composed of a dense rectangular outer shell and a hollow 
inner compartment.  This non-uniform strucutre and density will cause differing attenuation 
as a function of gantry angle as was observed and ranged from 3.5% to 17% for the 
measurements with the mesh top.  A larger magnitude of attenuation over the angles that 
intersected with the rails and imaging top was observed, but the trend was the same as the 
mesh top; the attenuation decreased and then increased as the rails were traversed which is 
consistent with the non-uniformity of the rails. This trend is similar to the Wagner study that 
found rail attenuation ranging from 8.83% to 17.01% for the Varian Exact Couch rails (20). 
An interesting inconsistency is observed at the data point at 180 degrees with the 
imaging couch top and rails in. At this location there is no relative attenuation measured, 
which seems to be inconsistent with our conclusion that the imaging couch top itself causes 
appreciable attenuation.  However, this could be due to a partial intersection of the beam 
with the rails that creates in-scatter from the rails into the middle of the couch, compensating 
for the attenuation of the couch top.  
 In conclusion, for specific aim 1, we observed attenuation by the rails and imaging 
couch top consistent, except for a higher measured attention by the mesh top, with published 
results in the literature. The dosimetric impact of this attenuation is evaluated in specfic aims 
2 and 3.  The mesh couch top was not observed to appreciably attenuate the beam as 
compared to the flat panel, imaging top and rails and will thus be explored only as an 
additional investigation within the discussion.   
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4.1.2 Specific Aim 2 
 Our results from the first part of specific aim 2, which evaluated the ability of the 
Eclipse TPS to accurately predict the dose pertubation caused by the Varian Exact Couch 
are shown in section 3.3.1 as percent differences between the measured absolute dose for a 
delivered plan and the TPS calculated dose for the hybrid plan that included the couch and 
rails in the same configuration as was delivered.  For all plans, both IMRT and RapidArc, 
and all rail configurations, we observed agreement of 0.7%.  Although having better 
agreement when the couch and rails were taken into account showed that the TPS 
represented a better measure of treatment delivery reality, we also wanted to compare our 
results to the results in the literature for similar studies.  
In comparing our results to the three other studies that also evaluted the ability of 
their respective treatment planning system to predict the attenuation through their couch 
strucutures, we found similar agreement with our study.  The study by Mihaylov et al found 
argeement between computed and measured values of predicted dose for variety of  set, 
open field-sizes within 2% (11).  The study by Myint et al found agreement within 2% as 
well when the treatment couch was incorporated into the Theraplan Plus v3.8 TPS via a CT 
image of the couch top (13).  Finally, the study by Prooijen et al also found agreement 
within 2% when CT images of their couches were incorporated into the Pinnacle TPS (14).  
We believe that our results, an average agreement of 0.7% or less, are better than the other 
results in the literature for two reasons:  Our agreement is better (0.7% compared to 2%) and 
for all except the Prooijen study, patient plans were not used for verification of their 
respective couch models.  Those other studies mentioned used static, open field beam 
through the couch and/or rails (depending on the features of their respective couch model) 
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into a phantom with an ion chamber. They then compared the predicted dose calculated in 
their TPS for that beam to the measured value.  The Prooijen study also verified the utlity of 
their TPS with the same type of phantom measurements, but additionally used film 
measurements with one 4-field IMRT plans with three posterior fields to verify the ability of 
their TPS to account for the couch and rails.  They found agreement within 2%, but as was 
previously mentioned, their rail model did not reflect the non-uniform structure of one of 
their couch rails and this measurment was only performed for one case.  From this, we 
concluded that the accurary of the Eclipse TPS to account for the couch and rails is better 
than the other methods for couch modeling presented in the current literature.   
One study was previously mentioned in the discussion evaluated the accuracy of the 
Eclipse TPS couch models in addition to measuring the attenuating properties of the couch 
and rails. A study by Wagner et al 2011 compared the accuracy of the couch parameters 
included in the Eclipse TPS to measured values (20). They found that the default HU values 
were in good agreement with the HU numbers they obtained from CT images for both the 
imaging couch top filling (-1000 default vs -995 optimal) and rails (200 default vs 225 
optimal). In contrast, the carbon plate’s HUs was set too high (-300 default vs -750 optimal). 
However, even with this disagreement, the overall resultant disagreement between Eclipse 
TPS calculated values of attenuation through the couch top and rails structures and measured 
values were only 0.84% + 0.15% with a 6 MV photon beam (20).  Although the 
disagreement is large between measured and default HU values, the resulting disagreement 
in measured dose is small and, furthermore, our agreement between predicted and measured 
dose was, on average, better than the value reported by Wagner et al when we used the 
default HU values.            
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 The results comparing our measurments to the clinical experience using the clinical 
IMRT QA protocol at MDACC are shown in section 3.3.2.  All plans had worse agreement 
when the couch and rails were not taken into consideration using the TPS compared to our 
results in section 3.3.1 that did account for the strucutures.  The disagreement varied from 
1.7% to 4.8% on average for the various configurations and delivery modalities.  An 
interesting point to highlight from this is that the MDACC passing criteria for absolute point 
dose for a clinical plan must have agreement within +3%.  This means that, on average, all 
of the IMRT and RapidArc plans delivered with the rails out failed our clinical passing 
criteria.  However, as mentioned, treatments are commonly performed leaving the rails out 
for this beam arrangmement.  The dose disagreement error is not detected because during 
IMRT QA, the rails are moved to avoid intersecting the beam, thereby avoiding these 
failures.  So, with our QA, we think the plans are passing with, on average, 1.7% 
disagreement but are in fact being delivered in a configuration that is at 4.8% disagreement. 
The potential impact of this error is addressed in the discussion along with recommendations 
on how to fix it in the conclusions. 
4.1.3 Specific Aim 3 
Evaluation of our DVH data gathered for all plan iterations for each patient for target 
coverage and dose showed that when the Varian Exact Couch with imaging insert and rails 
are not accounted for in treatment planning, there is, on average, clinically unacceptable 
losses of dose and coverage to target structures.  For the IMRT deliveries, every plan with 
the rails out failed our coverage criteria of 98% and 95% of prescription dose to the prostate 
and PTV, respectively.  There was a wide range of losses in coverage to both structures; for 
example, as seen in Table 3-19, coverage to the prostate drops to only 3% coverage for one 
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patient while it drops to just 80% for another.  These differences can result from a variety of 
factors: Each patient’s IMRT plans had different MU’s at each beam angle as shown in 
Figure 3-7, the volume of each patient’s prostate and PTV varied as mentioned in the 
appendix to this thesis, and the position of the patient on the modeled table also had some 
variability.  All of these factors can contribute the wide range of differences observed and 
would be expected in a given population of patients.  It should, therefore, be noted that the 
magnitudes of the losses of coverage are not meant to be true for all patients clinically, but 
rather, to highlight that often the effects of the couch and rails are unacceptable clinically. 
There was less loss of coverage observed for the IMRT plans with the rails in than 
with the rails out as shown in Table 3-20.  This was expected based on our clinical beam 
arrangement; our 8-field set-up only had two posterior fields at 225 and 135 degrees that 
only intersected with the rails when they were out laterally.  So, the coverage loss observed 
with the rails in is completely attributable to the effect of the couch top. This was verified in 
Table 3-21, which shows that the loss of coverage is the same for plans with the rails in and 
plans that have the couch top only.  As before, a wide variety of coverage losses were 
observed; as low as 62% prostate coverage was observed, while two patients showed no 
clinically significant loss of coverage for this configuration.  This could be attributed to the 
differences mentioned in the previous section between patient anatomy and patient plans.  
However, it is important to note that on average the presence of the couch top resulted in 
failure of planning criteria, although not to the same degree as with the rails in and, should, 
therefore, not be considered a negligible contributor to attenuation with IMRT.   
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An interesting discrepancy is seen for the target coverage losses for IMRT patients 1 
and 4 as shown in Table 3-19 through Table 3-21for which these patients did not lose a 
clinically significant amount of coverage with the rails in and imaging couch top only.  
However, this discrepancy is not seen when looking at those patients’ loses of target dose in 
Table 3-24 and Table 3-25; specifically that both patients lose an average amount of dose as 
compared to the other patients.  This seeming discrepancy is explained by looking at the 
mean doses to these patients’ targets.  Patients 1 and 4 had the highest mean doses to their 
prostates (79 and 78 Gy, respectively) which allowed them to lose an average amount of 
target dose without appreciably affecting their target coverage.  
In summary, for the losses in coverage to target structures observed with IMRT plans 
with varying couch and rail configurations, the rails contributed most to the loss in coverage 
(when beams intercepted the rails), while the couch top caused less loss.  While the couch 
top at times (patients 1 and 4) did not cause a clinically unacceptable loss in coverage, on 
average, a clinically unacceptable loss of coverage was observed.   
The results for dose loss to the target structures with IMRT delivery followed the 
same pattern: the rails caused the greatest loss of prescription dose on average (when 
intercepted) while the couch top contributed less.  On average, the mean loss of prescription 
dose to the prostate was 4.2% with the rails out and 2% for both rails in and couch top only.  
These would all be clinically unacceptable if they resulted in the mean dose to these targets 
being below the prescription dose of 76Gy. 
In comparing these results to the one study in the literature that evaluated dose and 
target coverage loss for IMRT patients by Prooijen et al, it is difficult to draw comparisons. 
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As previously mentioned, they retrospectively evaluated the impact of the couch and rails 
for five IMRT patients that presented intersection problems through posterior fields at the 
time of treatment.  They found up to a 3% reduction in PTV coverage and 0.1% to 1.3% loss 
of prescription dose, as defined by the 95% isodose line (14).  We cannot compare these 
results to ours for two reasons: the authors did not say which treatment couch, disease site, 
prescription, or beam arrangements were used on the five patients evaluated so we cannot 
assess if our results should be comparable, and secondly, they evaluated losses at the 95% 
isodose line while we evaluated losses at the 100% isodose line.  
The average losses in coverage to target structures with the RapidArc plans were 
found to be more alarming than those observed for the IMRT plans.  Table 3-38 shows that 
the coverage for rails out and rails in is comparable at 18% and 17%, respectively.  The 
contribution from the couch top alone, on average, caused a drop to 40% coverage.  This 
illustrates that for RapidArc treatments, the imaging couch top contributes most to the loss 
in target coverage, not the rails as with IMRT. This result makes sense because with our 2-
arc field arrangement, the couch top is intersected for more gantry angles and therefore more 
MUs than the rails.  Also, the loss in coverage being nearly identical with the rails in versus 
the rails out makes because, unlike IMRT, the rails are traversed by our 2-arcs regardless of 
their position. However, it should be noted that this trend was not observed in all patients.  
This is mostly likely due to the differing doses and dose distributions between the IMRT and 
RapidArc plans for the same patient.  
The dose loss to the target structures for our RapidArc plans were less than the losses 
observed for IMRT, but still could result in clinically unacceptable plans with approximately 
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3% prescription dose loss with both rails out and rails in, with 2% from the couch top alone.  
This means, unlike for IMRT, the imaging couch top contributed most to coverage and dose 
loss to target structures.  There are no studies published in the literature to-date investigating 
the dosimetric impact due to Arc Therapy, which is a novel feature of this work.  
The possible long-term impact of the target dose and coverage losses observed is 
depicted by the average TCP reduction of 7.7%.  The average loss of 7.7% in tumor control 
indicates that of the patients treated, 7.7% would be predicted to have tumor recurrence 
simply because the couch and rails were not taken into account during treatment planning. 
However, there are many uncertainties to consider when using TCP models. Many of the 
input parameters to the model (e.g., γ 50, TCD50, a) are dependent upon clinical data that are 
related to patient outcome, which can cause variance in the TCP values. Also, there is the 
further complication of life expectancy in typical prostate cancer patients, whose typical age 
at diagnosis is 68 years and who have an average life expectancy of 78.5 years (1,21); this 
factor may prevent manifestations of recurrences on the order predicted by the TCP 
modeling.   
The results from our novel investigation of the effect of the couch and rails on the 
rectal and bladder critical structures highlight a possible problem with our current DVH 
constraints.  The values associated with dose tolerances to structural volumes are based on 
long-term studies in late effect toxicity to patients.  If, as is shown in Table 3-30 for IMRT 
plans and Table 3-47 for RapidArc plans, patients with posterior treatments have been 
having less of the volume of their normal tissue structures receiving high doses, then are the 
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DVH constraints truly representing toxicity limits for patient populations?  Answering this 
would require much additional investigation but is an important clinical question to raise.   
Another interesting point is evaluating how well the losses in dose to the targets 
matched with the losses to the ion chamber measured during IMRT QA.  The losses in dose 
is, on average, consistent with the loss in dose measured with our IMRT QA protocol; on 
average there was a 4.8% dose loss to the ion chamber using our IMRT QA protocol for a 
plan with the rails out and an average of 4.2% dose loss to the prostate expected from our 
DVH information. The largest difference between IMRT QA measurement and DVH 
expectation was observed in one patient with a 6.2% dose loss to ion chamber and a 4.1% 
loss to the prostate from DVH information.   While our clinical IMRT QA protocol seems to 
reasonably predict the loss of dose we observed with our DVH’s, such assessment provides 
no information about the spatial distribution of the dose loss or coverage loss.  
4.1.4 Follow-Up Study: Mesh Couch Top               
The Varian Exact Couch comes with two couch top inserts: the solid carbon fiber 
imaging insert used for linacs with on-board imagers (OBI) and the thin, transparent mesh 
top insert used, typically, on non-OBI linacs.  The reason for the difference in couch tops is 
that the mesh design is visible in the KV-images taken with the OBI’s and so the imaging 
insert is used because it has a uniform density structure that does not show up on film.   
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Figure 4-1.  Varian Exact Couch with mesh top insert 
 
As both Varian Exact couch inserts are used clinically at MDACC, we decided to do 
an additional investigation into the dosimetric impact of the mesh couch top by creating a 
plan for each patient’s IMRT and RapidArc plans that included the unipanel mesh top only 
and repeat specific aim 3.  The results for the target coverage for the IMRT plans are shown 
below and show that, with the exception of the PTV coverage on patient 3, the presence of 
the mesh insert did not result in a clinical failure of coverage, unlike the imaging insert 
shown next to our results for the mesh insert in Table 4-2. It is important to note that the 
following tables compare only the impact of the couch top. The rails are additional 
attenuation that would need to be considered when evaluating the overall impact of a 
particular couch and rail configuration. 
Mesh Couch Top       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx Dose 100% 100% 100% 100% 100% 
PTV % Volume Coverage at Rx Dose 98% 96% 93% 95% 97% 
Table 4-1. Coverage of target structures at prescription dose for IMRT with mesh couch top only 
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IMRT Plans Mesh Couch Top Imaging Couch Top 
Prostate % Volume Coverage at Rx Dose 100% 84% 
PTV % Volume Coverage at Rx Dose 96% 79% 
Table 4-2. Average coverage of targets at prescription dose for IMRT plans comparing both couch tops 
 
Likewise, the loss of dose to target structures was less than with the imaging insert as 
shown in Table 4-3.  This average mean loss of 0.3% would likely not cause a failure in the 
mean dose required to have tumor control unless the mean dose to the prostate was exactly 
76 Gy when planned without the couch.  This acceptable dose reduction would only apply if 
the rails were not intersected by the beam. As shown in the results, the rails can have the 
greatest impact for IMRT, and would cause plan failure if intersected regardless of couch 
insert. 
IMRT Plan: 
Mesh Couch 
Top 
Imaging Couch 
Top 
Average Prostate Min Dose Loss (%) 0.4% 1.9% 
Average Prostate Max Dose Loss (%) 0.4% 1.8% 
Average Prostate Mean Dose Loss (%) 0.3% 2.0% 
Average PTV Min Dose Loss (%) 0.3% 1.5% 
Average PTV Max Dose Loss (%) 0.4% 1.9% 
Average PTV Mean Dose Loss (%) 0.3% 1.9% 
Table 4-3. Average percentage of minimum, maximum, and mean prescription dose loss from both couch tops  
 The results for the mesh top insert on our RapidArc plans are shown below in Tables 
4-4 and Table 4-5. Although the mesh top did not cause a clinically significant loss of target 
coverage to patient 2, the rest of the patient plans would not be acceptable even with the 
mesh top. However, the loss is much less than with the imaging couch as shown in Table 
4-5. 
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Mesh Couch Top       
Patient 1 2 3 4 5 
Prostate % Volume Coverage at Rx Dose 88% 99% 100% 79% 89% 
PTV % Volume Coverage at Rx Dose 93% 98% 91% 85% 93% 
Table 4-4. Coverage of target structures at prescription dose for RapidArc with mesh couch top only 
   
RapidArc Plans Mesh Couch Top Imaging Couch Top 
Prostate % Volume Coverage at Rx Dose 91% 40% 
PTV % Volume Coverage at Rx Dose 92% 57% 
Table 4-5. Average coverage of targets at prescription dose for RapidArc plans for both couch tops 
 
 The dose loss caused by the mesh insert, as with IMRT, was less than the imaging 
insert but still greater than the loss by the mesh insert in the IMRT plans.  However, with an 
average mean of 0.6% loss of prescription dose, it may not represent a clinically 
unacceptable loss in dose. However, because the rails cannot be avoided in RapidArc, it 
would not be possible to deliver with this little dose loss.  It merely demonstrates that the 
mesh top causes less of a loss than the imaging insert investigated throughout this thesis. 
RapidArc Plans Mesh Insert Imaging Insert 
Average Prostate Min Dose Loss (%) 0.6% 2.2% 
Average Prostate Max Dose Loss (%) 0.6% 2.1% 
Average Prostate Mean Dose Loss (%) 0.6% 2.0% 
Average PTV Min Dose Loss (%) 0.6% 2.4% 
Average PTV Max Dose Loss (%) 0.5% 1.6% 
Average PTV Mean Dose Loss (%) 0.6% 2.1% 
Table 4-6. Average percentage of minimum, maximum, and mean prescription dose loss from both couch tops 
 
 
 
84 
 
Chapter 5 Conclusions  
The attenuation of the posterior treatment fields for both IMRT and RapidArc plans by 
the Varian Exact couch with imaging insert and support rails causes a clinically 
unacceptable loss of dose and coverage to the target structures associated with prostate 
cancer treatment if these support structures are not taken into account.  The magnitude of the 
loss of target coverage and dose is clinically significant to the extent that ignoring the couch 
and rails structures resulted in plan failure, on average, for all IMRT and RapidArc couch 
and rail positions.  This is important as it represents a clinically unacceptable difference 
between what dose and coverage we think a plan is will deliver to a patient and the reality of 
what is being delivered.   
To solve this discrepancy for IMRT plans, the rails should be moved during 
treatment to avoid the attenuating the treatment beam.  This could be done by noting what 
gantry angles would intersect with the rails out and rails in and checking for intersections at 
those angles during patient treatment.  This would avoid the approximately 2% dose loss and 
49% coverage loss to the prostate we observed.  However, as was observed, the imaging 
couch top itself contributes to unacceptable losses in some of our patient cases and since it is 
not avoidable during treatment, it should be accounted for in the TPS either using a 
validated couch model like the Eclipse TPS provides or increasing posterior MU’s by an 
appropriate couch factor.  For clinics that are especially high volume and/or cannot 
implement such changes in planning protocol, using the mesh top couch in lieu of the 
imaging couch top was shown in our discussion to result in acceptably small dose and 
coverage loss assuming the rails are moved.  If the rails were not moved and left in the out 
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position with the mesh top, a dose loss of 2.4% and, most likely, a clinically unacceptable 
coverage loss to the prostate. 
Solving this discrepancy for RapidArc plans is more difficult since the rails cannot 
be moved during treatment due to the continuous nature of treatment delivery.  Moreover, 
the imaging couch top contributed substantially to the dose loss.   Also, as we showed in the 
discussion, although the mesh top caused less loss of dose and coverage to target structures, 
they were still clinically unacceptable.  When taken together, the mesh top and rails should 
cause approximately 1.6% dose loss to the prostate for either rail position.   Therefore, both 
the couch top (imaging and mesh) and rails need to be accounted for in treatment planning 
to be consistent with what we clinically want to deliver to achieve effective tumor control.  
Finally, for IMRT QA it is essential that the rail position used during QA is the same 
as during treatment.  Although some institutions may have a policy of moving the rails 
during treatment, as noted, this is not a universal practice and IMRT QA is commonly done 
to avoid the rails while this is not always done for treatment, resulting in large dose and 
coverage losses.  As shown, this would be most important to implement for IMRT plans but 
there was also a slight difference observed in RapidArc with rail position and, therefore, 
consistent placement of rails for QA and treatment should also be implemented.    
We hypothesized that the presence of the Varian Exact imaging couch top and rails 
would not demonstrate a clinical impact for IMRT and Arc Therapy. For this work, a 
clinical impact was defined to be a change that would cause a failure of the plan based on 
clinical planning criteria used in our clinic: 98% coverage of prescription dose to the 
prostate, 95% to the PTV, meeting of normal tissue DVH constraints.  Our results have 
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shown our hypothesis to be false since the presence of the couch top and rails caused failure 
of the clinical target dose and coverage planning criteria; this was manifest as a reduction in 
TCP.       
5.2 Future Work 
Future work on this project should include consulting with the department of 
radiation physics about the feasibility of implementing couch models in future treatment 
planning.  Other additional work should include a similar investigation on the effect on other 
disease sites with different beam arrangements, investigation of the effect of other clinically 
used couches, and further use of our DVH information to assess the predicted decrease in 
tumor control probability (TCP) anticipated by the loss of dose to our target structures using 
an appropriate biological model. 
Finally, the most involved future endeavor should be a re-evaluation of our current 
DVH constraints for normal tissue structures and how accurately they fit the late-term 
effects they are meant to prevent given the discrepancies we noted between the doses 
structures were believed to receive clinically and the doses they received in reality.  This 
could be done by retrospective analysis of the effect of the couch and rails on critical 
structures for patients’ outcome data that was used to arrive at the current clinical DVH 
constraints as well as a normal tissue complication probability (NTCP) modeling analysis of 
our DVH results. 
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Chapter 6 Appendix 
6.1 IMRT Plans 
A sampling of the data from all five patient IMRT plans is included in this appendix.  
Patients representing a small, medium, and large prostate volume were chosen to for 
inclusion in the appendix.  Patient 1 with a prostate volume of 33 cm3 was determined to be 
a small prostate volume in our sample of patients, Patient 3 with a prostate volume of 47 
cm3 was determined to be a medium prostate volume in our sample of patients, and patient 4 
with a volume of 74.5 cm3 was determined to be a large prostate volume in our sample of 
patients.    
6.1.1 IMRT DVH 
The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow, 
respectively in Figure 6-1 through Figure 6-3 displayed below.  Each clinical scenario plan, 
which is the outer most pair of prostate and PTV lines in each plan passed MDACC’s 
planning criteria of at least 98% coverage of the prostate and 95% coverage of the PTV by 
the prescription dose of 76 Gy.  The next pair of PTV and prostate DVH lines shifted to the 
left, closest to the clinical scenario represents both the plans with the rails in and the imaging 
couch top only for all patients.  The inner most set of prostate and PTV DVH lines, the 
greatest shift left from the clinical scenario represents the plan with the rails out in all the 
patients. 
The DVH’s for the three patients shown are consistent with the appearance of the 
other DVH’s in terms of how the target DVH lines are shifted.  The full DVH’s are shown 
here and one can note a difference in the normal tissue dose-volumes (shown in yellow for 
88 
 
the bladder and green for the rectum) which is due to differing planning constraints and 
differing normal tissue volumes. 
 
Figure 6-1.  Relative volume vs absolute dose DVH for patient 1 (small prostate).  The PTV, prostate, rectum, 
and bladder are displayed in blue, red, green, and yellow, respectively  
 
 
Figure 6-2.  Relative volume vs absolute dose DVH for patient 3 (medium prostate).  The PTV, prostate, 
rectum, and bladder are displayed in blue, red, green, and yellow, respectively  
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Figure 6-3.  Relative volume vs absolute dose DVH for patient 4 (large Prostate).  The PTV, prostate, rectum, 
and bladder are displayed in blue, red, green, and yellow, respectively  
 
6.1.2 IMRT Isodose Comparisons 
The representative clinical scenario IMRT plan next to its subsequent iterations with 
the rails out, rails in, and couch top only for the same CT slice are displayed below in Figure 
6-4 though Figure 6-12. The clinical scenario on the left panel of each figure shows 
complete coverage of the prostate (in blue colorwash) by the 76 Gy isodose line (in red), 
indicating complete coverage of the structure on that CT slice when the couch and rails are 
not included in the plan, as is clinical practice at MDACC.  The image in the right panel 
show the changes in the prescription isodose coverage of the target when the couch and rails 
are considered. 
The medium and large sized prostates show a pattern of the prescription isodose lines 
breaking around the target consistent with the representative data presented in the thesis.  
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The small prostate shown with patient 1, however, has a different pattern.  There is no 
visible breaking of the prescription isodose lines on the target.  This could be attributed, as 
was noted, that the patient had the fewest plan MU’s through the posterior field of any 
patient and, most importantly, the highest mean dose to the prostate which could explain the 
lack of coverage loss by the prescription isodose line. 
 
Figure 6-4.  Clinical scenario IMRT plan (left panel) and rails out plan (right panel) for patient 1 (small 
prostate) with prostate shown in red colorwash  
 
Figure 6-5.  Clinical scenario IMRT plan (left panel) and rails in plan (right panel) for patient 1 (small 
prostate) with prostate shown in red colorwash 
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Figure 6-6.  Clinical scenario IMRT plan (left panel) and imaging couch top only plan (right panel) for patient 
1 (small prostate) with prostate shown in red colorwash 
 
 
Figure 6-7. Clinical scenario IMRT plan (left panel) and rails out plan (right panel) for patient 3 (medium 
prostate) with prostate shown in blue colorwash 
  
 
Figure 6-8. Clinical scenario IMRT plan (left panel) and rails in plan (right panel) for patient 3 (medium 
prostate) with prostate shown in blue colorwash 
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Figure 6-9. Clinical scenario IMRT plan (left panel) and imaging couch top only plan (right panel) for patient 
3 (medium prostate) with prostate shown in blue colorwash 
 
 
Figure 6-10. Clinical scenario IMRT plan (left panel) and rails out plan (right panel) for patient 4 (large 
prostate) with prostate shown in blue colorwash  
 
Figure 6-11. Clinical scenario IMRT plan (left panel) and rails in plan (right panel) for patient 4 (large 
prostate) with prostate shown in blue colorwash 
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Figure 6-12. Clinical scenario IMRT plan (left panel) and imaging couch top only (right panel) for patient 4 
(large prostate) with prostate shown in blue colorwash 
 
6.1.3 IMRT Plan Subtractions 
The IMRT plan subtractions show areas of dose loss between the clinical scenario 
and plans that including the patient support structures.   Figure 6-13 through Figure 6-21 
represent the spatial areas and magnitudes of dose loss between the clinical scenario and the 
plans that account for various components and configurations of the couch and rails.   
The spatial patterns of dose loss along the posterior fields are consistent for all the 
patients shown.  The only differences are in magnitude of dose losses which were previously 
addressed for each patient.  
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Figure 6-13.  Clinical scenario IMRT Plan subtracted from rails out plan for patient 1 (small prostate) with 
prostate shown in blue colorwash  
 
Figure 6-14.  Clinical scenario IMRT Plan subtracted from rails in plan for patient 1 (small prostate) with 
prostate shown in blue colorwash 
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Figure 6-15.  Clinical scenario IMRT Plan subtracted from imaging couch top only plan for patient 1 (small 
prostate) with prostate shown in blue colorwash 
 
 
Figure 6-16.  Clinical scenario IMRT plan subtracted from rails out plan for patient 3 (medium prostate) with 
prostate shown in blue colorwash  
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Figure 6-17.  Clinical scenario IMRT plan subtracted from rails in plan for patient 3 (medium prostate) with 
prostate shown in blue colorwash 
 
 
Figure 6-18.  Clinical scenario IMRT plan subtracted from imaging couch top only plan for patient 3 (medium 
prostate) with prostate shown in blue colorwash 
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Figure 6-19.  Clinical scenario IMRT plan subtracted from rails out plan for patient 4 (large prostate) with 
prostate shown in blue colorwash  
 
Figure 6-20.  Clinical scenario IMRT plan subtracted from rails in plan for patient 4 (large prostate) with 
prostate shown in blue colorwash 
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Figure 6-21.  Clinical scenario IMRT plan subtracted from imaging couch top only plan for patient 4 (large 
prostate) with prostate shown in blue colorwash 
 
6.2 RapidArc Plans 
A sampling of the data from all five patient RapidArc plans is included in this appendix.  
Since the same planning CT images were used for the IMRT and RapidArc plans, the same 
representative patients (patients 1, 3, and 4) are shown in this section representing small, 
medium, and large prostate volumes from our study population.    
     6.2.1 RapidArc DVH 
The PTV, prostate, rectum, and bladder are displayed in blue, red, green, and yellow, 
respectively in Figure 6-22 through Figure 6-24.  Each clinical scenario plan which is the 
outer most pair of prostate and PTV lines in each plan passed MDACC’s planning criteria of 
at least 98% coverage of the prostate and 95% coverage of the PTV by the prescription dose 
of 76 Gy.  The next pair of PTV and prostate DVH lines shifted to the left, closest to the 
clinical scenario represents the imaging couch top only for all patients and indicates that the 
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couch top itself contributes to coverage loss to target structures.  The inner most two sets of 
prostate and PTV DVH lines, the greatest shift left from the clinical scenario, represent the 
plan with the rails out and rails in for all the patients.  The rails out and rails in target DVH 
lines are very close and sometimes overlapping. This is reasonable because, as the beam 
arrangement shows in Figure 2-4 in section 2.2.2, both the couch top and rails are 
intersected during delivery.  Coverage to the target structures is lost when either the imaging 
couch top or rails are intersected. 
 The pattern of DVH target line shifts for all patients is consistent with respect to the 
order noted in the section above.  The magnitudes of the coverage losses vary and are not 
easily quantifiable using these figures and were addressed quantitatively in section 3.3.4.  
Also, the normal tissue dose-volumes varies greatly between patients and is due to differing 
absolute volumes, anatomy location, and dose constraints used for planning.  However, all 
clinical DVH criteria were met for the normal tissue structures.   
 
Figure 6-22.  Relative volume vs absolute dose RapidArc DVH for patient 1 (small prostate).  The PTV, 
prostate, rectum, and bladder are displayed in blue, red, green, and yellow, respectively 
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Figure 6-23.  Relative volume vs absolute dose RapidArc DVH for patient 3 (medium prostate).  The PTV, 
prostate, rectum, and bladder are displayed in blue, red, green, and yellow, respectively 
 
Figure 6-24.  Relative volume vs absolute dose RapidArc DVH for patient 4 (large prostate).  The PTV, 
prostate, rectum, and bladder are displayed in blue, red, green, and yellow, respectively 
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6.2.2 RapidArc Isodsose Comparisons 
The representative clinical scenario RapidArc plan next to its subsequent iterations 
with the rails out, rails in, and couch top only for the same CT slice are displayed below in 
Figure 6-25 through Figure 6-33. The clinical scenario on the left panel of each figure shows 
complete coverage of the prostate (in blue colorwash) by the 76 Gy isodose line (in red), 
indicating complete coverage of the structure on that CT slice when the couch and rails are 
not included in the plan, as is clinical practice at MDACC.  The image in the right panel 
show the changes in the prescription isodose coverage of the target when the couch and rails 
are considered.   
Unlike the IMRT isodose figures shown, RapidArc isodose comparisons show a loss 
in isodose coverage of the target for each patient that is consistent with the mean patient data 
shown in the thesis. 
 
Figure 6-25. Clinical scenario RapicPlan (left panel) and rails out plan (right panel) for patient 1 (small 
prostate) with prostate shown in blue colorwash 
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Figure 6-26. Clinical scenario RapicPlan (left panel) and rails in plan (right panel) for patient 1 (small 
prostate) with prostate shown in blue colorwash 
 
 
Figure 6-27. Clinical scenario RapicPlan (left panel) and imaging couch top only (right panel) for patient 1 
(small prostate) with prostate shown in blue colorwash 
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Figure 6-28. Clinical scenario RapicPlan (left panel) and rails out plan (right panel) for patient 3 (medium 
prostate) with prostate shown in blue colorwash 
 
Figure 6-29. Clinical scenario RapicPlan (left panel) and rails in plan (right panel) for patient 3 (medium 
prostate) with prostate shown in blue colorwash  
 
Figure 6-30. Clinical scenario RapicPlan (left panel) and imaging couch top only plan (right panel) for patient 
3 (medium prostate) with prostate shown in blue colorwash 
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Figure 6-31. Clinical scenario RapicPlan (left panel) and rails out plan (right panel) for patient 4 (large 
prostate) with prostate shown in blue colorwash 
 
Figure 6-32. Clinical scenario RapicPlan (left panel) and rails in plan (right panel) for patient 4 (large prostate) 
with prostate shown in blue colorwash 
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Figure 6-33. Clinical scenario RapicPlan (left panel) and imaging couch top only plan (right panel) for patient 
4 (large prostate) with prostate shown in blue colorwash 
 
6.2.3 RapidArc Plan Subtractions 
The RapidArc plan subtractions show areas of dose loss between the clinical 
scenario and plans that including the patient support structures.  Figure 6-34through Figure 
6-42 show the spatial areas and magnitudes of dose loss between the clinical scenario and 
the plans that account for various components and configurations of the couch and rails.   
The plan subtractions shown for each patient are consistent in the pattern of dose 
loss; specifically the loss is along the position of the rails.  The magnitude of dose loss 
varies and was addressed in the thesis.  These variances, as noted, can be due to the amount 
of MU’s going through the posterior arcs.  
 
Figure 6-34.  Clinical scenario RapidArc Plan subtracted from rails out plan for patient 1 (small prostate) with 
prostate shown in blue colorwash  
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Figure 6-35.  Clinical scenario RapidArc Plan subtracted from rails in plan for patient 1 (small prostate) with 
prostate shown in blue colorwash 
 
Figure 6-36.  Clinical scenario RapidArc Plan subtracted from imaging couch top only plan for patient 1 
(small prostate) with prostate shown in blue colorwash 
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Figure 6-37.  Clinical scenario RapidArc plan subtracted from rails out plan for patient 3 (mean prostate) with 
prostate shown in blue colorwash  
 
 Figure 6-38.  Clinical scenario RapidArc plan subtracted from rails in plan for patient 3 (mean prostate) with 
prostate shown in blue colorwash 
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Figure 6-39.  Clinical scenario RapidArc plan subtracted from imaging couch top only plan for patient 3 
(mean prostate) with prostate shown in blue colorwash 
 
Figure 6-40.  Clinical scenario RapidArc plan subtracted from rails out plan for patient 4 (large prostate) with 
prostate shown in blue colorwash  
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Figure 6-41.  Clinical scenario RapidArc plan subtracted from rails in plan for patient 4 (large prostate) with 
prostate shown in blue colorwash 
 
Figure 6-42.  Clinical scenario RapidArc plan subtracted from imaging couch top only plan for patient 4 (large 
prostate) with prostate shown in blue colorwash 
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